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Oncogenic mutations in BRAF and PTEN as regulators of the host immune response in primary 
cutaneous malignant melanoma
PP Aung,1 R Gupta,2 Y Kluger,2 N Wajapeyee2 and M Mahalingam1 1 Dermatopathology 
Section, Dept of Dermatology, BUSM, Boston, MA and 2 Pathology, Yale University School 
of Medicine, New Haven, CT
Background: To date the genetic factors responsible for determining the immune response in mela-
noma are not fully known. Given this, the aim of our study was to identify the genetic determinant 
of the immune response by focusing on the major genetic pathways such as BRAF, NRAS, KRAS 
and PI3Kinase/PTEN shown to be deregulated in malignant melanomas. Expression of indoleamine 
2,3-dioxygenase immunosuppressive enzyme (IDO), previously implicated in immune evasion 
in cancer and under genetic control of a melanoma tumor suppressor was also studied. Design: 
Archival materials were retrieved from the pathology files of the Skin Pathology Laboratory, Boston, 
MA. A total of 67 (n=33 for with and n=34 for without a brisk host response) cases were identified 
as meeting criteria for inclusion in the study. In all cases, direct DNA sequencing was performed 
on BRAF; NRAS1; NRAS2 and KRAS genes and immunohistochemistry (IHC) was performed using 
antibodies against PTEN, indoleamine 2,3-dioxygenase (IDO) and CD3. Results:While we found 
no correlation between the frequency of mutations in BRAF, RAS or NRAS genes and a brisk host 
response in malignant melanoma, the frequency of PTEN expression in melanomas with a brisk host 
response (22/33 cases, 66.7%), was higher compared to the non-brisk response (15/34 cases, 44.1%) 
while that of IDO lower (15/33 cases, 45.5% versus 21/34 cases, 61.8%) lower. Conclusions: Our 
results indicate that PTEN expression and lack of IDO expression predicts a brisk host response in 
a subset of malignant melanomas and can be used as potential molecular biomarkers for recruiting 
melanoma patients for immunotherapy.    
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Histological features of superficial spreading melanoma are associated with and predictive 
of CDKN2A germline mutations
MR Sargen,1,2 PA Kanetsky,2 J Newton-Bishop,3 N Hayward,4 G Mann,5 N Gruis,6 M Tucker,7 
A Goldstein,7 G Bianchi-Scarra,8 S Puig9 and DE Elder1 1 Pathology and Laboratory 
Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 2 Biostatistics and 
Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 
PA, 3 University of Leeds, Leeds, United Kingdom, 4 QIMR Berghofer Medical Research 
Institute, Brisbane, QLD, Australia, 5 Westmead Millennium Institute, Sydney, NSW, 
Australia, 6 Leiden University Medical Center, Leiden, Netherlands, 7 Division of Cancer 
Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 8 University of Genoa, 
Genoa, Italy and 9 University Hospital Clinic of Barcelona, Barcelona, Spain
The purpose of this study was to determine if histological features can help to predict carriage 
of a CDKN2A germline mutation in patients with and without a family history of melanoma. We 
performed a case-control study of 24 histopathologic features of melanoma cases from CDKN2A+ 
melanoma-prone kindreds (N=123), with controls from sporadic cases (unknown family history, no 
genetic testing, N=81) and from CDKN2A- families (N=120). Cases and controls were retrieved from 
the Melanoma Genetics Consortium (GenoMEL) database and were matched on age, sex, and AJCC 
thickness categories. For the comparison of CDKN2A+ cases with CDKN2A- controls, higher page-
toid scatter grade (OR=1.45, 95% CI: 1.07-1.97, p=0.018) and increased pigmentation (OR=1.69, 
95% CI: 1.11-2.59, p=0.015) were associated with the presence of a germline mutation. For the 
comparison of CDKN2A+ melanomas with the combined control group of CDKN2A- and sporadic 
melanomas, higher pigmentation (OR=1.49, 95% CI: 1.03-2.15, p=0.035) was also associated with 
the presence of a germline mutation. Classification and Regression Tree (CART) analysis utilizing 
the variables of mitotic rate, cell type, and pigment was able to predict genotype with greater than 
70% accuracy utilizing less than two tree splittings. Histological features of superficial spreading 
melanoma, including high pagetoid scatter and dense pigmentation, are associated with and strongly 
predictive of the presence of a CDKN2A germline mutation in melanoma.    
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Aberrant expression of miR-25 promotes pigmentation disorders in vitiligo by repressing 
MITF and MYO5A
Q Shi, S Guo, W Zhang, S Li, K Li, Z Jian, G Wang, T Gao and C Li Dermatology, Xijing 
Hospital, Xi, China
Although miRNAs have been shown to play a role in various diseases, little is known about their 
expression and function in vitiligo, an acquired cutaneous disorder characterized by dysfunction 
and/or loss of melanocytes with underlying pathogenesis poorly understood. In the present study, 
we compared the expression profiles of miRNAs in vitiligo serum with paired healthy control 
and identified 48 differentially expressed miRNAs. Among these miRNAs, miR-25, a significantly 
up-regulated miRNA in vitiligo serum, was further studied in greater detail, because two of its target 
genes, MITF and MYO5A, play critical role in melanocytes. We proved that increased miR-25 
significantly inhibited protein expression of MITF and MYO5A by directly interacting with 3ʹUTR 
of the two genes in melanocytes. Moreover, we demonstrated that restoration of miR-25 inhibited 
cell cycle progression, and promoted H2O2-induced apoptosis of melanocytes. Further functional 
studies revealed that miR-25 down-regulated expression of TYR and TYRP1, as well as tyrosinase 
activity, thus imparing melanin biosynthesis, and disturbed intracellular transportation of melano-
somes. Together, these results suggest that increased expression of miR-25 in vitiligo lesions can 
exert a crucial influence on the maintenance and function of melanocytes via repressing MITF and 
MYO5A, thus contribute to the depigmentation process of vitiligo.    
692
Mitochondrial dynamics regulate melanogenesis through ROS activation in B16F1 cells
E Kim,1 Y Na,2 S Park,1 N Park,2 H Lee,2 J Cho2 and D Cho1 1 Graduate School of East-West 
Medical Science, Kyung Hee University, Yongin, Republic of Korea and 2 Skin Research 
Institute, Amorepacific R&D Center, Yongin, Republic of Korea
Mitochondria are highly dynamic organelles that continuously divide and fuse in healthy cells 
Mitochondria dynamics (fission and fusion) control the processes related to mitochondria biogenesis, 
subcellular localization, and distribution as well as their morphology. Mitochondria fission is regu-
lated by dynamin-related protein 1 (Drp1). On the other hand, the mitochondria fusion is mediated 
by mitofusin1 and 2 (Mfn1/2) and optic atrophy protein 1 (Opa1). Mitochondria are the primary 
producers of reactive oxygen species (ROS), which are involved in melanogenesis. However, the 
role of mitochondrial dynamics on melanogenesis is completely unknown. In the present study, we 
found that mitochondrial dynamics contribute to melanogenesis through regulation of ROS activa-
tion. Down regulation of Drp1 increased melanin production and tyrosinase expression as well as 
mitochondrial elongation in B16F1 cells. In addition, treatment of mdivi-1, a chemical inhibitor of 
Drp1 up-regulated the expression levels of tyrosinase, TRP1, and MIFT as much as that of α-MSH. 
In contrast, depletion of Opa1 strongly induced massive mitochondrial fragmentation and inhibited 
α-MSH-stimulated melanogenesis in B16F1 cells. Treatment of CCCP, a mitochondrial uncoupling 
agent highly induced mitochondrial fragmentation. Moreover, the α-MSH-mediated melanin pro-
duction was efficiently suppressed by treatment of CCCP. The mitochondrial fission induced by 
either genetic or chemical agent resulted in increased of ROS activation. The inhibition of ROS by 
a scavenger significantly reduced the anti-melanogenic effect of CCCP in α-MSH-stimulated B16 
F1 cells. Collectively, these results suggest that mitochondrial dynamics regulates melanogenesis 
through the generation of ROS in B16F1 cells.    
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CD155/TIGIT interaction is an immune checkpoint regulating antimelanoma immune 
responses
T Inozume,1 T Yaguchi,2 J Furuta,1 K Harada,1 Y Kawakami2 and S Shimada1 1 Dermatology, 
University of Yamanashi, Yamanashi, Japan and 2 Keio University School of Medicine, 
Division of Cellular Signaling, Institute for Advanced Medical Research, Tokyo, Japan
Blockade of immune checkpoint is a promising strategy to activate antimelanoma immune 
responses. Recent clinical trials show that blockade for CTLA-4 and PD-1 is effective in the treatment 
of melanoma. However, impact of other immune checkpoints on antitumor immune responses is 
still unclear. In this study, we demonstrate the role of the TIGIT/CD155 interaction in antimelanoma 
immune responses. TIGIT is an inhibitory receptor expressed on T cells, and CD155 is one of the 
cognate ligands expressed on tumor cells or antigen-presenting cells. First, we confirmed that 
CD155 is constitutively expressed on various types of tumor cells including melanoma cells, and 
that expression is upregulated on melanoma cells by IFN-γ stimulation. We then demonstrate that 
overexpression of CD155 on melanoma cells suppresses the cytokine release and cytotoxicity of 
melanoma-specific CTLs, and this effect was reversed by TIGIT blockade. In vivo, overexpression 
of CD155 on melanoma cells dramatically attenuates the effect of antimelanoma vaccine therapy. 
In addition, CD155 and PD-L1 synergistically suppress the activation of melanoma-specific CTLs. 
These results strongly suggest that CD155-TIGIT interaction is another immune checkpoint that 
should be blocked for enhancement of antimelanoma immune responses.    
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TLR2 and TLR3 agonists utilize Rab11a and Rab27a to transfer melanosome to keratinocytes
S Koike, K Yamasaki, T Yamauchi, K Tsuchiyama and S Aiba Dermatology, Tohoku 
University Graduate School of Medicine, Sendai, Japan
Innate immune stimuli such as microbe molecules restlessly influence epidermis where human 
melanocytes reside. We have examined how innate immunity affects pigmentation. We observed 
that TLR2 agonist HKLM and TLR3 agonist poly(I:C) increased melanin release from melanocytes (IID 
2013 in Edinburgh, The manuscript is in submission). We also revealed poly(I:C) increased mRNA 
and protein expression and accumulation of Rab27A, which facilitate melanosome transportation 
to cell membrane. SiRNA for Rab27A (siRab27A) abrogated melanosome transfer to neighboring 
keratinocytes by poly(I:C). However, HKLM did not affect Rab27A expression, and siRab27A failed 
to suppress melanosome transfer to keratinocytes by HKLM. Thus TLR2 and TLR3 stimuli utilize 
different mechanisms for melanosome transfer to keratinocytes. To further explorer machineries 
involved in melanosome transfer by innate immunity, we hypothesized HKLM induce melanosome 
transfer through filopodia-mediated function. We examined the dynamics of filopodia-relating mol-
ecules Rab17, Rab11a and Rab11b by HKLM stimuli, and knockdown their expression by siRNA. 
HKLM stimuli increased Rab11a expression protein for about 2-fold in normal human melanocytes. 
While Rab11a localized perinuclear in unstimulated melanocytes, HKLM alters Rab11a distribution 
diffusely in cytosol. Rab11a knockdown by siRNA decreased melanosome transfer to keratinocytes 
by HKLM to 25%. SiRNA for Rab17 and Rab11b did not affect melanosome transfer by HKLM and 
poly(I:C). SiRNA for Rab27A strongly suppressed melanosome transfer by poly(I:C) to 30% but not 
by HKLM, suggesting Rab27A dominantly affected melanosome transfer by TLR3 agonist poly(I:C) in 
normal human melanocytes. These indicated that TLR2 agonist HKLM alters the Rab11a distribution 
and utilizes Rab11a to transfer melanosome to keratinocytes. Since Rab11a is reported to involve 
in the filopodia formation, TLR2 might regulate the melanosome transfer trough filopodia. Thus the 
innate immunity modifies the pigmentation process in skin.    
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Co-existence of psoriasis and melanoma in a large urban population: A cross-sectional study
T Bhattacharya,1 B Nardone,1 A Rademaker,2 M Martini,1 A Amin,1 H Al-Mudaimeagh,1 
D Schneider3 and DP West1 1 Department of Dermatology, Feinberg School of Medicine, 
Northwestern University, Chicago, IL, 2 Department of Preventive Medicine, Feinberg School 
of Medicine, Northwestern University, Chicago, IL and 3 Northwestern University Clinical 
and Translational Sciences (NUCATS) Institute, Feinberg School of Medicine, Northwestern 
University, Chicago, IL
Although psoriasis (P) has been linked to increased malignancy risk, such as non-melanoma skin 
cancer, an association with cutaneous melanoma (CM) remains unclear. The aim of this study was 
to determine if there is an association between P and CM (01/2001-11/ 2013) in 1,857,125 individ-
uals, through an adult-based, urban and academic-based electronic medical record database. Odds 
Ratio (OR) was calculated for CM in those with P vs. no P. Subjects were identified by ICD-9 codes 
(psoriasis: 690.0, 690.1; melanoma: 172.0 - 172.9; atopic dermatitis (AD): 691.8). CM diagnosis 
was included only if it was reported after a P diagnosis. We identified a total of 12,554 P subjects 
of which 82 had a subsequent diagnosis of CM. Using Fisher’s exact test, we found a significant 
association for CM in P (OR= 2.09; 95%CI 1.68-2.60; p <0.0001). Using logistic regression analysis 
to adjust for phototherapy, a confounding factor for CM in P, we found that an association of CM 
with P was still detectable (OR= 2.16; 95%CI 1.72-2.70; p <0.0001). To minimize detection bias 
related to P subjects receiving comprehensive skin examinations, we performed the same analysis 
for association between CM and AD. We found a total of 6,480 subjects with a diagnosis of AD, of 
which 9 had a subsequent report of CM. We found a significant inverse association between AD and 
CM (OR= 0.43; 95%CI 0.22-0.83; p=0.008). Our findings suggest that CM is associated with P in 
this population. However, various other potentially important confounding factors were not included 
in this analysis. Further studies to explore this association in other populations are warranted.   
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A study on the mechanism of stimulating effect of Cryptanthus on mouse melanoblast
M Kang,1 J Byun,1 H Park,2 H Lee,2 E Kim2 and J Shin1 1 Department of Dermatology, Inha 
University School of Medicine, Incheon, Republic of Korea and 2 Department of Biological 
Engineering, Inha University, Incheon, Republic of Korea
Vitiligo is an acquired hypomelanotic disorder characterized by hypomelanotic macules of various 
sizes which is caused by the loss of melanocytes. Current treatment modalities are directed towards 
restoring of pigmentation by stimulating melanocytes, however melanocytes are missing in the 
vitiligo lesions which attributes to the unsatisfactory treatment results. However, melanoblasts are 
present in the outer root sheath of hair follicles and these cells may serve as melanocyte reservoir 
and provide sources for repigmentation. In a screening experiment to find potent melanogenetic 
herbal medicine, extract of Cryptanthus was found to be effective in inducing melanogenesis and 
migration in melanocytes and melanoma cells. In this study, different concentrations of extract of 
Cryptanthus were added to melb-a mouse melanoblast to study effect on differentiation, migration 
and viability. Melanin content and cell viability were measured and a transwell migration assay was 
done. The results were compared to that of negative control treated with 10.0μg/L of DMSO and 
positive control treated with 10.0μg/L of α-MSH. Also, in order to elucidate the signaling pathway, 
phosphorylation and expression of extracellular signal-regulated kinase(ERK) and cAMP response 
element binding protein(CREB) were evaluated using western blotting analysis. Melanin content 
in Cryptanthus treated melb-a mouse melanoblast was increased in a dose-dependent manner and 
130% increase compared to α-MSH treated cells without affecting cell viability. Cell migration 
showed 203% increase after treatment with Cryptanthus compared to α-MSH. Western blot revealed 
that phosphorylation of CREB and ERK were increased after treatment with Cryptanthus extract. In 
conclusion, Cryptanthus seems to induce differentiation of mouse melanoblast through activation 
of ERK and CREB pathway and it may be a good candidate for vitiligo treatment.    
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Overexpression of mitochondrial sirtuin deacetylase SIRT3 promotes the survival of human 
melanoma cells
J George,1,2 M Nihal,1,2 CK Singh,1 W Zhong1,2 and N Ahmad1,2 1 University of Wisconsin, 
Madison, WI and 2 William S. Middleton VA Medical Center, Madison, WI
Despite advances and development in therapy, incidence and mortality due to melanoma continue 
to rise. Therefore, it is extremely important to increase our efforts to understand the genetics and 
mechanisms of melanoma development and progression. Mammalian sirtuins (SIRT1-7), which are 
nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylases are known to have 
a variety of molecular functions and have emerged as critical proteins in aging, stress resistance 
and metabolic regulation. Interestingly, their role in cancer is extremely complex and somewhat 
controversial with dichotomous functions (tumor promoter versus tumor suppressor) that seem to 
be dependent on cell types. SIRT3 is a major mitochondrial deacetylase with crucial roles in regu-
lating various functions. Here, we determine the role and functional significance of SIRT3 in human 
melanoma. Using real-time PCR and immunoblotting, we found that compared to normal human 
melanocytes (NHEMs), SIRT3 is significantly upregulated in human melanoma cells (SK-MEL-28, 
WM35 and G361) at mRNA and protein levels. In addition, employing tissue microarray containing 
clinical melanoma and normal skin tissues, we found that SIRT3 is markedly upregulated in human 
melanoma tissues. Further, a short hairpin RNA (shRNA)-mediated knockdown of SIRT3 in human 
melanoma cells resulted in 1) G1-phase cell cycle arrest, 2) increase in senescence-associated 
β-galactosidase (SA-β-gal) activity, 3) senescence associated hetrochromatin formation (SAHF), 4) 
decrease in cell migration, 5) increase in protein levels of p53, phospho-p53 (Ser15), p21Waf1, pRb 
and p16INK4a and, 6) increase in p53 transcriptional activity. Furthermore, a forced overexpression 
of SIRT3 resulted in an increase in cell growth and clonogenic survival in Hs249T melanoma cells. 
Taken together, this study suggests a pro-proliferative role of SIRT3 in human melanoma. How-
ever, further studies are needed to validate these findings and to ascertain the exact mechanism 
of SIRT3 in melanoma.    
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Host genetic factors are associated with nevus count and dermoscopic patterns: Preliminary 
results from the study of nevi in children (SONIC)
I Orlow,1 J Satagopan,1 K Cheung,1 Y Xu,1 S Dusza,1 S Oliveria,1 A Geller,2 M Bishop,3 
M Berwick,4 M Marchetti,1 M Fonseca,1 X Wu,1 K White,4 M Weinstock,5 A Scope,6 
A Marghoob1 and A Halpern1 1 Memorial Sloan-Kettering Cancer Center, New York, NY, 2 
Harvard School of Public Health, Boston, MA, 3 Framingham Public Schools, Framingham, 
MA, 4 University of New Mexico, Albuquerque, NM, 5 Brown University, Providence, RI and 
6 Tel Aviv University, Tel Aviv, Israel
High melanocytic nevus count is one of the important risk factors for melanoma. It has been pro-
posed that nevi distinguished by their dermoscopic patterns represent distinct biologic subsets of 
nevi that differ in their association with sun exposure, phenotype and genotype. This study aimed 
to investigate associations between host genetic factors, nevus count, and dermoscopic patterns of 
nevi in children. We genotyped 85 single nucleotide polymorphisms (SNPs) in 353 buccal samples 
from 5th grade participants of the ongoing Study Of Nevi In Children from the Framingham school 
system. Dermoscopic images of 853 nevi from 290 students were categorized into homogeneous, 
globular, reticular, and complex patterns. Associations between SNPs and baseline nevus count 
were determined by multivariate regression for all 353 children adjusting for sex, and race/ethnicity. 
Associations between SNPs and reticular and globular dermoscopic patterns in relation to homoge-
neous patterns were determined by polytomous regression. IRF4 rs12203952, showed the strongest 
association with log nevus count (RR=1.59, 95% CI 1.29-1.97, p<0.0001). Using homogeneous nevi 
as reference we identified 5 SNPs in the IRF4, TERF2, TERT, SLC45A2 genes significantly associated 
with dermoscopic patterns (p<0.05): rs12203592, rs35390, rs2853676, and rs251796 with globular 
patterns while rs2242652 and rs2853676 were associated with reticular patterns. Host genetic 
factors appear to be associated with nevus count and with distinct dermoscopically-defined subsets 
of nevi in childhood. Additional analyses in larger cohorts are required to confirm these findings.   
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Methotrexate upregulates death receptors/ligands and enhances apoptosis of human mel-
anoma cell lines
M Nihal,1,2 J Wu1 and GS Wood1,2,3 1 Dermatology, School of Medicine and Public Health, 
Madison, WI, 2 Paul P. Carbone Comprehensive Cancer Center, Madison, WI and 3 Wm. S. 
Middleton VA Medical Center, Madison, WI
Melanoma, the most aggressive form of skin cancer, is notoriously resistant to all available modalities 
of cancer therapy. Methotrexate (MTX) is an antifolate, antimetabolite and antineoplastic compound 
that competitively inhibits dihydrofolate reductase which in turn inhibits DNA synthesis by hindering 
the conversion of dihydrofolate to the active tetrahydrofolate required for thymidine and purine 
synthesis. MTX is an effective drug for several types of cancer including breast cancer, lung cancer, 
head and neck cancers, lymphomas and leukemias. We have shown recently that MTX also acts as 
a DNA methylation inhibitor by blocking synthesis of S-adenosylmethionine, the principal methyl 
donor for DNA methyltransferases. In cutaneous T-cell lymphoma, MTX increases Fas/CD95 death 
receptor by decreasing Fas promoter methylation, resulting in enhanced FAS-mediated apoptosis. 
The objective of this study was to explore the effects of MTX in human melanoma. Our in-vitro data 
indicate that MTX variably inhibits the growth and viability of WM35, A375, G361, Hs294T SK-Mel2 
and SK-Mel28 melanoma cells. MTX treatment also resulted in apoptosis as evident by Annexin 
V positivity and, senescence as evident by β-galactosidase induction. Furthermore, MTX caused 
increased transcript and protein levels of extrinsic apoptotic pathway factors FasL, Fas, TRAIL and 
TRAIL receptors (DR4, DR5), albeit at different levels in different cell lines. Initial pyrosequencing 
studies showed that this increased expression was associated with FasL and Fas promoter demeth-
ylation in at least some cases. Overall, our findings suggest that the ability of methotrexate to upreg-
ulate death receptors/ligands and enhance melanoma apoptosis might make it a useful component 
of novel combination therapies designed to target multiple melanoma pathways simultaneously.   
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Induction of melanocytes from multilineage-differentiating stress-enduring (Muse) cells 
derived from human adipose tissue
T Yamauchi,1 K Tsuchiyama,1 F Ogura,2 S Wakao,2 S Koike,1 K Yamasaki,1 M Dezawa2 and 
S Aiba1 1 Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan 
and 2 Stem Cell Biology and Histology, Tohoku University Graduate School of Medicine, 
Sendai, Japan
Multilineage-differentiating stress-enduring (Muse) cell is a multipotent somatic stem cell existing 
mesenchymal tissues such as dermis. Muse cells have unique characters; (1) having low or no 
telomerase activity, (2) having pluripotency to differentiate into representative cells of all three 
germ layers, (3) not developing tumors, (4) exhibiting self-renewal ability, (5) expressing unique 
glycosphingolipid, stage specific embryonic antigen 3 (SSEA3). We have isolated SSEA3-positive 
Muse cells from cultured human fibroblasts and generated melanocytes by stimulating Muse cells 
with 10 factors including Wnt3a (JID 2013). 6 weeks after culturing, Muse cell-derived melanocytes 
(Muse-MC) expressed melanocyte markers MITF, tyrosinase and gp100 and showed tyrosinase 
activity. Using skin reconstitute culture model including Muse-MC, we confirmed localization of 
MITF and tyrosinase positive cells at the basal layer. These suggested that Muse cells differentiated 
into functional melanocytes. We aimed to clinical application and further examined if Muse cells 
isolated from human tissues can differentiate into melanocytes. We collected human adipose-de-
rived stem cells (ASC) from human adipose tissues obtained from surgical specimens. We identified 
2.5 ± 0.38% of SSEA3-positive cells in ASC (ASC-Muse). ASC-Muse expressed alkaline phosphatase, 
SMA, neurofilament, a-fetoprotein, indicating ASC-Muse possessed pluripotency. Using 10 factors 
for 6 weeks, ASC-Muse, but not from non-Muse ASC, induced melanocyte-relating molecules such 
as MITF de novo and showed tyrosinase activity. Using skin reconstitute culture model including 
ASC-Muse-derived melanocytes (ASC-Muse-MC), we confirmed ASC-Muse-MC migrate into the 
basal layer of reconstituted epidermis. These showed that functional melanocytes could be generated 
from human tissue-derived ASC-Muse without any external gene transduction.    
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Intrinsic aging and skin darkening: Aging-related changes in inflammatory cytokines can 
trigger the epidermal hyper-pigmentation
D Min, Y Na, H Lee and J Lee Skin Research Division, Amorepacific R&D Unit, Yongin-si, 
Republic of Korea
Wrinkle formation, loss of elasticity, and age spots are the common features of skin aging. In addition 
to these changes, skin darkening and abnormal pigmentations are usually accompanied with aging. 
However, the cause of this aging-related hyper-pigmentation is not clearly understood yet. For this 
reason, we set up an in vitro model system that can study aging-related skin darkening and tried to 
find out the factors that can affect the epidermal pigmentation according to aging. To investigate 
the aging-related epidermal hyper-pigmentation, we constructed pigmented skin equivalent (PSE) 
models. Neonatal (PSE-N) and 40 years (PSE-40) models were constructed with fibroblast and 
keratinocyte in different ages, however the same neonatal melanocyte was used in both models to 
confirm the effect of aging on epidermal pigmentation. The darkness of skin was measured with 
L-value and confirmed by epidermal total melanin assay. Cellular senescence and the activation 
of melanogenic enzymes were observed in mRNA level. The changes in inflammatory cytokines 
were analyzed with protein array technique. Although we used the same melanocyte to both PSE-N 
and PSE-40 models, epidermal pigmentation of PSE-40 was much greater than that of PSE-N. The 
epidermal melanin contents of PSE-40 was about 2-fold (p=8.19298E-07) higher than that of PSE-
N. The L-value was 44.15 for PSE-40 and 48.36 for PSE-N. The gene expression of p21, MITF, 
Tyrosinase, TRP1, and TRP2 were increased in PSE-40. The expression of C5a, G-SCF, GM-CSF, 
GROa, IL-1ra, IL-6, IL-8, IP-10, I-TAC, MCP1, and SerpinE1 showed statistically significant differ-
ence between PSE-N and PSE-40. In this study, by using novel neonatal and aged pigmented skin 
equivalent models, we showed that skin aging can induce epidermal hyper-pigmentation through 
the activation of melanocyte and the changes in inflammatory cytokine expression profile can be 
a cause of aging-related epidermal hyper-pigmentation. These results suggest a new method that 
can improve the aging-related skin darkening and pigmentation disorders.    
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Breaking TRAIL resistance in organotypic 3D melanoma
H Vörsmann,1 S Beissert2 and D Kulms1,2 1 Inst. of Cell Biology and Immunology, Univ. of 
Stuttgart, Stuttgart, Germany and 2 Dermatology, TU Dresden, Dresden, Germany
Despite remarkable efforts, metastatic melanoma still presents with significant mortality because 
tumors rapidly develop resistance to novel therapies thereby regaining tumorigenic capacity. 
Although genetically-engineered mouse models for metastatic melanoma have been developed, 
at present no model is available that reliably mimics the human disease and is suitable for study-
ing mechanisms of therapeutic obstacles including cell death resistance. In order to improve the 
increasing requests on new therapeutic alternatives, reliable human screening models are demanded 
that translate the findings from basic cellular research into clinical applications. By developing a 
human organotypic full skin equivalent, harboring melanoma tumor spheroids of defined sizes we 
have invented a cell-based model that recapitulates both the 3D organization and multicellular 
complexity of an organ/tumor in vivo but at the same time accommodates systematic experimental 
intervention. Using this novel vivo-like 3D model compared to regular 2D culture we could show 
significant differences in the therapeutical outcome to exist between both systems when investigating 
the sensitization of melanoma cells towards TRAIL by co-application of sublethal doses of UVB 
or cisplatin. While both treatment combinations killed the same cancer cell lines in 2D-culture, 
skin-equivalent-embedded melanoma spheroids are potently killed by TRAIL+cisplatin treatment but 
remain almost unaffected by the TRAIL+UVB combination. Consequently, we have established an 
organotypic human skin-melanoma model that will facilitate efforts to improve therapeutic outcomes 
for malignant melanoma by providing a platform for the investigation of cytotoxic treatments and 
tailored therapies in an innovative and physiological setting.    
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Elevated expression of CYP24A1 in nevi and early-stage skin melanomas
AA Brozyna,1 W Jozwicki,1 C Jochymski1 and AT Slominski2 1 Department of Tumor 
Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Lukaszczyk Memorial 
Hospital, The Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, 
Bydgoszcz, Poland and 2 Department of Pathology and Laboratory Medicine, Department of 
Medicine, University of Tennessee HSC, Memphis, TN
Under normal conditions levels of active form of vitamin D3 (1,25(OH)2D3) are precisely reg-
ulated in a negative feedback loop which includes inhibition of expression of 1α-hydroxylase 
(CYP27B1), and stimulation of the expression of 24-hydroxylase (CYP24A1), which deactivates 
1,25(OH)2D3 through its metabolism staring by hydroxylation at C24. In tumors, this mechanism 
can be deregulated. Previously we have shown negative correlation of vitamin D receptor (VDR) and 
CYP27B1 expression with progression of skin melanoma, its aggressiveness and overall or disease 
free survivals. Therefore, we analysed changes in CYP24A1 expression in nevi, skin melanomas 
and metastases. The samples of 6 normal skins, 15 benign melanocytic nevi, 58 melanomas and 25 
metastases obtained from 67 patients were subjected to anti-CYP24A1 immunostaining. CYP24A1 
expression was assessed based on both staining intensity and percentage of CYP24A1-positive cells 
and analyzed in relation to clinicopatomorphological features. In melanocytic tumors the level 
of CYP24A1 was increased when compared to normal epidermis. The statistically highest mean 
CYP24A1 level was observed in nevi and early stages (stage I-II and pT1-2) of melanomas (p=0.0076 
and p<0.001 versus normal epidermis, respectively). Furthermore, the CYP24A1 expression posi-
tively correlated with nuclear and cytoplasmic VDR (r=0.3035, r=0.0161 and r=0.4587, r=0.0004, 
respectively) and CYP27B1 (r=0.02756, p=0.0276). Lower CYP24A1 expression correlated with 
presence of ulceration (p=0.0034) and amelanotic phenotype (p=0.0024). In conclusion, local 
vitamin D endocrine system affects melanoma behavior and elevated level of CYP24A1 appears to 
have important impact on formation of melanocytic nevi and melanomagenesis or progression at 
early stages of tumor development.    
704
The roles of endogenously produced melatonin and its metabolites in pigmentary system
T Kim,1 Z Lin,2 WJ Tidwell,1 W Li2 and AT Slominski1,3 1 Pathology and Laboratory Medicine, 
University of Tennessee Health Science Center, Memphis, TN, 2 Pharmaceutical Sciences, 
University of Tennessee Health Science Center, Memphis, TN and 3 Medicine, University of 
Tennessee Health Science Center, Memphis, TN
Skin cells have shown to be able to metabolize melatonin into 6-hydroxymelatonin(6(OH)M), 
N1-acetyl-N2-formyl-5-methoxykynuramine(AFMK) and 5-methoxytryptamine(5-MT) depending on 
the cell type. In this study, we determined that melatonin and its metabolites were endogenously 
produced in human epidermis differently from person to person. The production of melatonin was 
high in black young(30s to 50s), white old(60s to 90s) and white female people while the production 
of AFMK was high in white male people. Productions of 6(OH)M and 5-MT were similar between 
young and old, black and white, and male and female people. To define biological functions of 
these metabolites in pigmentary system we tested their effects on proliferation and melanogenesis 
in human melanoma (SKMEL-188) and normal epidermal melanocytes. DNA incorporation studies 
have shown dose-dependent anti-proliferative effects of melatonin and its metabolites in normal 
human melanocytes and SKMEL-188 line. Testing of tyrosinase activity and melanin content, mel-
atonin and its metabolites, except 5-MT, showed lack of significant effects on pigmentation of in 
melanoma cells. In contrast, 5-MT stimulated L-tyrosine induced melanin pigmentation and tyrosi-
nase activity in SKMEL-188. However, melatonin and its metabolites inhibited tyrosinase activity in 
normal melanocytes. These results imply that cell pigmentation is not associated with cell growth 
inhibition in SKMEL-188, while anti-proliferative effects on normal melanocytes are well related 
with inhibition of tyrosinase activity. According to these studies, melatonin and its metabolites 
are produced endogenously in human epidermis and they are good candidates for further testing 
as therapeutics of hyper-proliferative disorders such as melanoma or as anti-pigmentary agents. 
Regulation of their endogenous production/metabolism can serve as a strategy for cosmetic or 
therapeutic purposes.    
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Comparison of predictive models for non-sentinel lymph node tumor positivity in melanoma
CJ Gustafson,1 R Yaar,2,3 KH Chen,1 SC Chen,1 C Cohen2 and B Stoff1 1 Dermatology, 
Emory University School of Medicine, Atlanta, GA, 2 Pathology, Emory University School of 
Medicine, Atlanta, GA and 3 Aurora Diagnostics GPA Laboratories, Greensboro, NC
Background: The standard of care for melanoma patients with tumor in the sentinel lymph node 
(SLN) is complete lymph node dissection (CLND).Given the morbidity associated with CLND, 
several predictive models for nonsentinel node (NSN) status have been created, including those 
by Gershenwald et al., Murali et al., and Cadili et al. Objective: To compare predictive models for 
NSN tumor positivity by Gershenwald et al., Murali et al., and Cadili et al. using the Emory Mel-
anoma Database. Methods: Using chart review and histopathologic/micrometric evaluation, data 
were collected on melanoma patients with tumor in SLN(s) who underwent subsequent CLND at 
Emory from 1995-2005. Variables included patient age, gender, Breslow thickness, site of primary 
melanoma, number of SLNs harvested, largest size of SLN metastasis, total size of SLN metastases, 
proportion of SLNs with metastases, regression in the primary tumor, and perinodal invasion in the 
SLN. Chi-square analyses were used to determine the ability of each scoring system to predict NSN 
positivity as well as the relationship of each variable with NSN status. A p-value less than 0.05 was 
deemed statistically significant. Results: 104 patients had tumor detected in SLN(s), of which 6 had 
positive NSNs (5.8%). The mean patient age was 49.5 years (SD 14.7), 65 (63%) were male, and the 
mean Breslow thickness was 2.96mm (SD 2.04). None of the three models were predictive of NSN 
tumor positivity. Examining individual variables, only the site of primary melanoma was significantly 
related to NSN positivity (p=0.03). Of note, number of SLN harvested (p=0.08) and proportion of 
harvested SLN with metastases (p=0.10) trended toward significance. Conclusion: None of the 
published models were predictive of NSN status in our melanoma population. Individual variables 
from each model are promising as a basis for an additional scoring system to be developed at Emory.   
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 Inflammasomal pathways may modulate the dynamic equilibrium between melanoma stem 
cell-like cells and differentiated transiently amplifying cells
SL Schneider,1 AL Ross1 and JM Grichnik1,2,3 1 Department of Dermatology and 
Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, FL, 2 Sylvester 
Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL 
and 3 Interdisciplinary Stem Cell Institute, University of Miami, Miller School of Medicine, 
Miami, FL
Despite current progress, advanced melanomas often recur and remain lethal. Melanoma stem-like 
cells may be most resistant to treatment and reactivation of their growth may be responsible for 
recurrence. The processes that control the equilibrium between proliferating cells and quiescent 
stem-like cells have not been fully defined. We are interested in whether inflammasomal pathways 
may play a role as they have been implicated in melanomagenesis. P2X7 and PANX1 are plasma 
membrane channels that act synergistically to regulate the inflammasome. MITF is a transcription 
factor that promotes melanocyte differentiation and proliferation. As anticipated, immunofluores-
ence microscopy (IF) revealed that MITF correlated with the proliferative marker Ki67 and flow 
cytometry (FC) identified an increased percentage of MITF-low cells in G0/G1. This data indicates 
that MITF-low, less proliferative cells are present in the melanoma population and likely includes the 
more stem-like cells. We then found that P2X7- and PANX1-low cells correlated with MITF-low cells 
suggesting a potential role in MITF regulation. To explore, we inhibited P2X7 and PANX1 using BBG 
and probenecid, respectively. Western blot, IF, and FC illustrated that inhibition of P2X7/PANX1 led 
to a decrease in MITF and Ki67 expression suggesting a transition to a less differentiated and less 
proliferative state in vitro. Inflammasomal pathways may have the capacity to control the dynamic 
equilibrium between melanoma stem cell-like cells and differentiated transiently amplifying cells. 
Because inhibition of P2X7/PANX1 places cells in a less proliferative state, it may become possible 
to use these pathways therapeutically to prevent melanoma recurrence by inhibiting differentiation 
of any post-treatment residual tumor stem-like cells.    
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Sensitization of melanoma cells to TNFα treatment via modulation of mTORC1 pathway
S Flashner,1 D Calianese,1 G Cammarata,1 C Best,1 G Yang2 and Y Wan1 1 Biology, 
Providence College, Providence, RI and 2 Dermatology, Beijing Friendship Hospital, Beijing, 
China
Although the causes of melanoma are becoming clear, the treatments remain limited. This is due 
largely to still undiscovered, potentially complex mechanisms. Our previous studies have shown 
that EGFR plays important roles in ovarian cancer cell proliferation and metastasis. However, we 
found that melanoma cells, with either mutated EGFR or other EGFR family members, resist oxidative 
stress and exhibit constitutive activation of mTORC1 pathway and S6 ribosomal protein phosphor-
ylation. In melanoma cells, we also observed that antioxidases, such as catalase, are up-regulated, 
compared to their counterparts, normal melanocytes. Clinically, TNFα has been tested for the 
treatment of melanoma. Our data showed that in human skin melanocytes, TNFα induces NFκB 
activation in a time and dose dependent manner. However, melanoma cells display delayed p65 
translocation in response to TNFα treatment. Based on our preliminary data, we hypothesize that 
modulation of mTOR pathway-mediated antioxidases would sensitize melanoma cells to respond 
to TNFα treatment. Our confocal microscopy and Western blot data showed that melanoma cells 
express antioxidases and antioxidants inhibit TNFα-induced NFκB activation. Rapamycin, an mTOR 
inhibitor, inhibits catalase expression and enhances the response to TNFα treatment in melanoma 
cells. Taken together, our data provide insights into the understanding of the molecular mechanisms 
of melanoma cells’ resistance to oxidative stress and TNFα treatment. Sensitization of melanoma 
cells with mTOR inhibitors may enhance the efficacy of TNFα therapy.    
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Glucose deprivation alters cell survival signals in melanoma cells
G Cammarata,1 D Calianese,1 V Schwartz,1 J Swanson,1 G Yang2 and Y Wan1 1 Biology, 
Providence College, Providence, RI and 2 Dermatology, Beijing Friendship Hospital, Beijing, 
China
Cancer cells use alternate cellular signaling pathways in order to proliferate and expand aggressively. 
This may make it possible to target using certain cancer therapies. In this study, we investigated the 
effects of reduced glucose concentrations on cell signaling molecules in human melanoma cells. We 
observed that reduction of glucose, from 25 mM to 0.1 mM, results in morphology alteration and 
inhibition of growth as well as modification to internal signaling pathways. The cytoskeleton was 
disrupted after 48 hours, as shown with decreased cell dendricity. Inhibition of growth was found 
to be correlated with decreasing glucose concentrations in medium, as was depletion of nutrients 
and changes in pH of the extracellular environment. Reduction in pH could be a mechanism of 
the cancer cells to proliferate and survive, the result of heavy production of lactic acid caused by 
increased rate of glycolysis, or both. Levels of p-S6, p-AMPK, p-ERK and p-MEK were shown to 
be increased by glucose deprivation at 6 hours, suggesting that the cancer cells are fighting back 
in order to survive. Phosphorylated S6 ribosomal protein, as well as ACC, decreased with glucose 
deprivation at 48 hours while p-AMPK increased. This suggests that high levels of stress lead to 
eventual cellular shutdown. Finally, GLUT1 and survivin, an anti-apoptotic molecule, were shown to 
be increased at 24 hours under glucose deprivation. Collectively, our data suggest that combination 
of glucose deprivation with inhibitors of cell survival signals may be better therapeutical options 
for the treatment of melanoma.    
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Upregulation of miR-519d contributes to melanosphere formation and epithelial to mesen-
chymal transition
Y Liao,1 C Lin1 and M Kuo2 1 Department of Dermatology, National Taiwan University 
Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan and 2 Graduate 
Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan
Increasing evidence suggests that there is a unique cell subpopulation in melanomas that can form 
nonadherent melanospheres under serum-free stem cell medium. These sphere-forming cells have 
been demonstrated to possess cancer stem cell-like activities and play important roles in tumor 
progression, metastasis, and epithelial to mesenchymal transition (EMT). Although miRNAs are 
crucial for cancer stem cell function as well as EMT, to date there have been no reports of miRNA 
expression profiling in stem-like melanospheres. The goal of the study was to characterize the 
miRNA profiles in melanospheres and to determine the roles of specific miRNA in melanoma 
progression. Through a genome-wide microRNA array based platform to screen for differentially 
expressed miRNAs between nonadherent sphere-forming and adherent parental A2058 melanoma 
cells, we discovered a characteristic set of miRNAs with significant upregulation. Among them, an 
up to 8-fold increase of miR-519d in melanospheres compared to the control was found. Over-ex-
pression of miR-519d increased cell migration, invasion and adhesion of human A2058 melanoma 
cells. In addition, upregulation of miR-519d influenced the levels of the EMT-associated genes; 
the expressions of mesenchymal markers N-cadherin and Vimentin were highly elevated, while 
the expression of epithelial marker E-cadherin was reduced. Comparing to the control, enhanced 
metastatic behavior of miR-519d-overexpressed cells was found by murine lung metastasis assay. 
We also validated the protein expression of the predictive targets of miR-519d including CDKN1A/
p21 and PTEN. Taken together, these results suggest that miR-519d promotes melanoma progression 
and the higher metastatic ability may result from EMT.    
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Generation of pigmented human 3D skin equivalents containing iPSC-derived melanocytes, 
keratinocytes and fibroblasts
K Gledhill,1 Z Guo,1 M Ito,1 C Higgins,1 N Umegaki-Arao1 and A Christiano1,2 1 Dermatology, 
Columbia University, New York, NY and 2 Genetics and Development, Columbia University, 
New York, NY
Currently, human 3D skin equivalents lack the necessary degree of complexity required to fully 
recapitulate the environment found in in vivo skin. In part, this contributes to the high drug attri-
tion rate during clinical trials as adverse effects which may only manifest themselves under such 
dynamic conditions are not discovered sooner. Therefore, it is clear that more complex human 
3D skin equivalents are urgently required to ensure the efficient use of limited time and resources 
and maximise their clinical relevance. One of the major factors currently limiting the complexity 
of 3D skin equivalents is the difficulty in isolating and expanding multiple cell types from an often 
inadequately sized skin biopsy. Therefore, we have focused on exploiting the unlimited growth 
potential and capacity for differentiation of iPSCs to develop a 3D skin equivalent built entirely 
from iPSC-derived fibroblasts, keratinocytes and melanocytes. To date, we have generated human 
3D skin equivalents, consisting of iPSC-derived fibroblasts and keratinocytes, and shown that they 
are comparable to those assembled using freshly isolated somatic cells. We recently produced 
iPSC-derived melanocytes, and generated a pigmented 3D skin equivalent derived from three iPS 
cell types. Moreover, we have shown that our iPSC-derived keratinocytes are capable of melanin 
uptake from normal epidermal melanocytes by using a 2D co-culture model, and are currently 
investigating whether the iPSC-derived melanocytes can also transfer melanin to iPSC-derived 
keratinocytes. Pigmented 3D skin equivalents have the potential to introduce a new level of cellular 
complexity to conventional skin grafts, and provide a model with which to evaluate drug side effects 
such as skin hyperpigmentation using in vitro testing models. Moreover, such a construct can be 
linked with other tissue equivalents in a microphysiological ‘human-on-a-chip’ platform to more 
accurately predict adverse responses to drugs.    
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Increased endogenous oxidative levels correlate to increased iron in melanocytes
E Pelle,1,2 X Huang,2 Q Zhang,3 N Pernodet,1 DB Yarosh1 and K Frenkel2 1 R&D, Estee Lauder 
Research Laboratories, Melville, NY, 2 Environmental Medicine, New York University School 
of Medicine, New York, NY and 3 R&D, ImClone Systems/Eli Lilly, Branchburg, NJ
Melanocytes are specialized neural crest-derived cells that produce melanin providing coloration 
and protection to the skin. Although UV exposure to human skin can induce oxidative stress in 
melanocytes, oxidative mechanisms also operate at basal levels in processes unique to melano-
cytes, such as melanogenesis. Here, we investigated their endogenous oxidative state as compared 
to normal human epidermal keratinocytes (NHEK) in order to gain new insight into melanocytic 
biology. Previously, we showed that NHEK contain higher levels of hydrogen peroxide (H2O2) 
than melanocytes and that it can migrate from NHEK to melanocytes by passive permeation. Nev-
ertheless, despite lower concentrations of H2O2, we now report higher levels of oxidative DNA in 
melanocytes as indicated by increased levels of 8-oxo-2’-deoxyguanosine (8-oxo-dG): 4.49 (± 0.55 
SEM) 8-oxo-dG/106 dG compared to 1.49 (± 0.11 SEM) 8-oxo-dG/106 dG for NHEK. Glutathione 
(GSH) another biomarker for antioxidant status was also lower in melanocytes (3.14 nmoles (± 
0.15 SEM)/cell) in comparison to NHEK (5.98 nmoles (± 0.33 SEM)/cell). Cellular bioavailable 
iron was also measured as a function of ferritin concentration and found to be nearly four-fold 
higher in melanocytes than in NHEK. Further, ferritin levels in melanocytes were also higher than 
in hepatocarcinoma cells, an iron-rich cell, and indicate that higher relative iron levels may be 
characteristic of melanocytes. In order to account for the increased oxidative DNA and lower GSH 
and H2O2 levels that we observe, we propose that iron may contribute to higher levels of oxida-
tion by reacting with H2O2 through a Fenton reaction leading to the generation of DNA-reactive 
hydroxyl radicals. In conclusion, our data support the concept of elevated oxidation as a normal 
parameter of melanocyte activity.    
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Use of a 3-dimensional epidermal model containing functional melanocytes for skin lightening 
and pigmentation studies
MA Bachelor, B Breyfogle, E Gustafson and M Klausner MatTek Corporation, Ashland, MA
Considerable interest exists in evaluating raw materials and/or skin care formulations which cause 
lightening of the skin. These products are utilized to alter one’s natural skin color or to combat 
skin pigmentation disorders such as melasma, post-inflammatory hyperpigmentation, and other 
hyperpigmentation lesions. In order to aid in the development and testing of such products, we 
have developed a melanogenesis/skin whitening protocol using MelanoDerm™ to evaluate both 
raw materials and skin lightening formulations. The use of this 3D model along with the whitening 
protocol can provide valuable in vitro data as an early screening tool for raw materials prior to the 
commencement of costly clinical trials. MelanoDerm is a highly differentiated, three-dimensional 
tissue culture model of human epidermis that contains normal human melanocytes (NHM) and 
keratinocytes (NHK). Skin lightening protocols have been produced containing NHM of varying skin 
phototypes which follow the expected pigmentation level of the donor tissue, i.e. black>Asian>Cau-
casian. Tissues are treated topically three times a week over a two to three week treatment period 
to mimic consumer application. Several over-the-counter skin lightening products were evaluated 
in cultures containing NHM from black and Asian donors. Over the treatment period, control cul-
tures became increasingly pigmented with retention of normal epithelial morphology. In contrast, 
tissues treated topically with cosmetic skin lightening agents containing tyosinase inhibitors such 
as kojic acid and magnesium ascorbyl phosphate remained distinctly lighter than control cultures. 
The skin lightening effect on treated tissues was quantitatively evaluated for melanin content using 
a solvable melanin assay. Treated tissues showed significant changes in overall melanin content 
as compared to water-treated tissues. The results described herein suggest that this model will be 
useful to study melanogenesis, skin lightening, and other pigmentation phenomena of skin in vitro.   
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Honokiol Bis-Dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant 
melanoma in vivo
M Bonner,1 I Karlsson,1 M Rodolfo,3 RS Arnold,4 E Vergani3 and J Arbiser1,2 1 Dermatology, 
Emory School of Medicine, Atlanta, GA, 2 Dermatology, Veterans Affairs Medical Center, 
Decatur, GA, 3 Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori via 
Venezian, Milan, Italy and 4 Urology, Emory School of Medicine, Atlanta, GA
The majority of human melanomas bear Braf mutations and thus are treated with inhibitors of Braf, 
such as vemurafenib. While patients with Braf mutations often demonstrate an initial dramatic 
response to vemurafenib, relapse is extremely common. Thus, novel agents are needed for the 
treatment of these aggressive melanomas. Honokiol is a small molecule compound derived from 
Magnolia grandiflora that has activity against solid tumors and hematopoietic neoplasms. In order 
to increase the lipophilicity of honokiol, we have synthesized honokiol DCA, the dichloroacetate 
ester of honokiol. Honokiol DCA as a single agent demonstrated significant activity against A375 
melanoma in vivo. We then examined its effect against a pair of melanomas, LM36 and LM36R, 
in which LM36R differs from LM36 in that LM36R has acquired vemurafenib resistance. Honokiol 
DCA demonstrated in vivo activity against LM36R (vemurafenib resistant) but not against parental 
LM36. In order to examine potential biomarkers for honokiol DCA response, we examined reactive 
oxygen levels in all three cell lines, and found that reactive oxygen levels in the sensitive cell lines 
(A375, LM36R) were significantly elevated compared with the resistant LM36 cell line. Gene chip 
analysis of A375 tumors in mice treated with vehicle vs honokiol DCA revealed upregulation of 
SDHB (succinate dehydrogenase B), AKR1B10 (aldo keto reductase 1B10), PIAS4 (E3 SUMO-protein 
ligase PIAS4 also known as protein inhibitor of activated STAT protein 4 (PIAS4) or protein inhibitor 
of activated STAT protein gamma) and TRAF2 (TNF receptor-associated factor 2). Honokiol DCA 
may act in part by reversing the Warburg phenomenon in vivo. Similar in vivo findings were revealed 
with a novel synthetic honokiol derivative, hexafluorohonokiol.    
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A new computer-vision approach for melanoma detection in dermoscopy
D Gareau,1 S Yagerman,2 M Suarez-Farinas,1 J Correa da Rosa,1 J DeFazio,2 L Chen,2 
A Marghoob2 and J Krueger1 1 Investigative Dermatology, The Rockefeller University, New 
York, NY and 2 Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, 
NY
Simple surgical excision can cure most melanomas that are localized to the skin. Clinical and der-
moscopic morphology has facilitated in finding early melanomas. However, there clearly is room for 
improvement since the mortality from melanoma is still on the increase. Towards this end, computer 
vision may augment the clinician’s cognition in identifying early melanoma. Computers can be 
trained to analyze lesions for the degree of asymmetry, border irregularity and color variegation, 
just to mention a few parameters. We developed and tested 30 computer vision metrics on Red/
Green/Blue dermoscopy images. Seventeen of these metrics (such as the variance of pigmented 
network branch lengths and colors) were effective, having higher values (P<0.05) for melanomas 
versus dysplastic nevi with mild to moderate dysplasia. Surprisingly, the metric measuring boarder 
asymmetry (i.e, degree of symmetry of the silhouette of the lesion) proved to be ineffective at dif-
ferentiating melanoma from nevi (p = 0.84). A neural network algorithm was trained on 88 lesions 
and tested on 32 lesions in a test set of 60 melanomas and 60 nevi. Five lesions, on which the 
algorithm failed to find the lesion boarder, were categorized as melanomas by default. The choice 
of the training and test sets was random and repeated ten times. At a clinically acceptable 100% 
sensitivity, the average specificity of the ten trials was 30%, which is encouraging since similar 
technology available commercially achieves only 10% specificity at 98.3% sensitivity.    
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Meiotic cohesion REC8 as a driver of chromosomal instability in melanoma
M Eller,1 S Lindsey,2 SL Schneider,1 J Escandon1 and JM Grichnik1 1 Dermatology, University 
of Miami School of Medicine, Miami, FL and 2 University of Miami School of Medicine, 
Miami, FL
Chromosomal instability (CIN), a process by which chromosomes are abnormally gained or lost, 
is a hallmark of cancer, particularly for melanoma. Although different models for CIN exist, the 
primary cause is unknown. Malignant cells also express germ cell proteins referred to as cancer testis 
antigens (CTAs). Some CTAs are germ cell proteins involved in meiosis. One such meiosis-specific 
protein is REC8, a subunit of the cohesion molecules that bind sister chromosomes after replication, 
promote the pairing of homologs and ensure cosegregation of sister chromatids during meiosis 1. 
REC8 also promotes crossover events of paired homologs, exchanging genetic information. Because 
of the high rate of CIN in melanoma, we examined melanoma lines and tissue for REC8 and fea-
tures of REC8-induced meiotic events in these mitotic cells. qRT-PCR showed that 7 melanoma 
tissue samples had REC8 RNA levels that on average were 5 times higher than from spleen, skin, 
heart, pancreas and thyroid (p=0.03). Western blot analysis demonstrated that REC8 was expressed 
at higher levels in 14 melanoma lines compared to 3 melanocyte lines, normal fibroblasts and 
keratinocytes (p<0.05). Also large polyploid melanoma cells contained high REC8 levels, consis-
tent with failure of proper nuclear division as demonstrated in REC8-expressing yeast. REC8 was 
also detected along metaphase melanoma chromosomes yet was absent in fibroblasts. Melanoma 
cells contained more anaphase bridges compared to normal fibroblasts (p<0.05), consistent with 
increased but unresolved, chromosome crossovers. FISH analysis of melanoma cells with probes 
marking chromosomes 3, 7 and 8 showed a higher frequency of homologous chromosomes paired 
in metaphase spreads from melanoma than from normal fibroblasts (p<0.05). Further, these DNA 
probes were also detected in anaphase bridges, suggesting the bridging chromosomes were formed 
by joined homologs. Together, these data suggest that REC8 and likely other meiotic CTAs may 
contribute to CIN in melanoma and likely other cancers.    
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Melanoma arises from common nevi after loss of p15-mediated proliferation arrest
A McNeal,1 K Liu,1 V Nakhate,1 C Natale,1 BC Capell,1,2 T Dentchev,1 S Berger,2 J Seykora1 
and TW Ridky1 1 Dermatology, University of Pennsylvania, Philadelphia, PA and 2 Cell and 
Developmental Biology, University of Pennsylvania, Philadelphia, PA
Most benign human melanocytic nevi harbor an activating BRAF(V600E) mutation which also 
serves as the primary oncogenic driver for most malignant melanoma. While activated BRAF pro-
motes a transient period of melanocyte proliferation leading to the formation of a nevus, typical 
nevi undergo growth arrest after reaching 3-5 mm in size, and remain quiescent thereafter. The 
mechanisms responsible for nevic growth arrest are not clear, but deciphering them may provide 
important insights into melanomagenesis as up to half of malignant melanomas arise within pre-ex-
isting nevi. Using primary melanocytes isolated from BRAF(V600E)-expressing human nevi, human 
nevi progressing to melanoma in vivo, and primary human melanocytes engineered to express 
BRAF(V600E), we show that BRAF(V600E) induces TGFβ secretion, which drives expression of 
the cyclin dependent kinase inhibitor (CDKI) p15, and halts proliferation. Growth arrest is p15 
dependent, and can be reversed by expression of a melanoma-associated mutant CDK4 resistant 
to p15 inhibition. We used nevus-derived melanocytes to establish a new in vivo human model of 
melanomagenesis utilizing genetically-defined human skin grafts. While TGFβ signaling is capable 
of restraining the oncogenic effects of BRAF(V600E) in benign nevi, this senescence-like phenotype 
is reversible and can permit melanoma development. As nevi can be melanoma precursors, this in 
vivo human melanoma model employing BRAF(V600E) nevus melanocytes may represent a human 
alternative to murine, or cell line-based approaches to study potential melanoma therapeutics.   
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Combining a Bcl-2 inhibitor with the retinoid derivative fenretinide targets melanoma cells 
including melanoma initiating cells
N Mukherjee, SN Reuland, Y Lu, Y Luo, M Fujita, YG Shellman and DA Norris Dermatology, 
University of Colorado, Denver, AMC, Aurora, CO
Recently multiple labs have verified the existence of Cancer Initiating Cells in melanoma, called 
melanoma initiating cells (MICs). MICs are thought to contribute to melanoma’s resistance to treat-
ments. It is proposed that the currently approved drugs do not target MICs and this may be one of 
the reasons for relapse. ABT-737, a small molecule Bcl-2 inhibitor, has shown promising results in 
treating cancers. However, it has not been very successful in treating melanoma as a single agent, 
and the anti-apoptotic protein Mcl-1 is the main contributor for this resistance. The synthetic retinoid 
fenretinide (4-HPR), can act as a Mcl-1 inhibitor, has shown success for treating breast cancers 
and it also targets leukemia stem cells. Thus, we tested whether the combination of ABT-737 (a 
Bcl-2/Bcl-XL/Bcl-W inhibitor) with 4-HPR (a potential Mcl-1 inhibitor) is effective in killing both 
the bulk of melanoma cells and MICs. MTS and Annexin-V assays indicated that the combination 
synergistically decreased cell viability and caused cell death in multiple melanoma cells lines but not 
in melanocytes. Mechanistic studies with shRNAs identified the upregulation of the pro-apoptotic 
protein Noxa as a significant contributor to the synergy. Furthermore, the combination treatment 
decreased the percentage of ALDHhigh cells (a marker of MICs) and caused significant disruption 
of the primary spheres (a functional assay for MICs) in multiple melanoma cell lines and in patient 
samples maintained in the mouse xenograft model. The combination also significantly prevented 
the formation of secondary spheres in multiple melanoma cell lines indicating that it inhibits self-re-
newability of MICs. Further in vivo experiments with mouse xenograft models are in progress. In 
summary, our results indicate that combining 4-HPR and ABT-737 has cytotoxicity not only for the 
bulk of melanoma cells, but also the MICs. Thus this combination is a promising treatment strategy 
for melanoma and warrants future clinical studies.    
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Combination of a gamma secretase inhibitor with the Bcl-2 inhibitor ABT-737 kills Melanoma 
Cancer Initiating Cells (MICs) by inducing apoptosis and inhibits the self renewability of MICs
N Mukherjee, AR Almeida, KA Partyka, J Schwan, Y Lu, Y Luo, M Fujita, YG Shellman and 
DA Norris Dermatology, University of Colorado, Denver, AMC, Aurora, CO
Multiple labs have recently verified the existence of cancer initiating cells in melanoma, which 
contribute to melanoma’s resistance to treatments. Recent approved drugs show exciting short term 
success, but many patients relapse or do not respond probably due to lack of the specific mutations 
targeted by these treatments and failure of these drugs to target the MICs. Thus, developing other 
treatment options targeting melanoma including MICs is still urgent. ABT-737, a small molecule 
Bcl-2/Bcl-XL/Bcl-w inhibitor, has shown promising results in cancer treatment but has not been 
successful in melanoma as a single agent. The anti-apoptotic protein Mcl-1 is the main contributor 
for this resistance. Thus, compounds targeting Mcl-1 could be a good candidate for combining 
with ABT-737. Therefore, in the present study we tested the effects of the combination of ABT-737 
with a Gamma Secretase Inhibitor (GSI, a Mcl-1 inhibitor) on melanoma cells and MICs. We found 
that the combination synergistically induced apoptosis, in multiple melanoma cell lines but not 
in melanocytes. The combination dramatically increased the Noxa/Mcl-1 ratio and studies with 
shRNAs revealed that knocking-down Noxa protected cells from combination-induced cell death. 
Moreover, the combination caused significant disruption of the primary spheres (a functional assay 
for MICs) compared to vehicle or individual treatments, and reduced the percentage of ALDHhigh 
cells (a marker of MICs) in melanoma cell lines as well as in patient samples maintained in mouse 
xenograft model. Lastly, the secondary sphere-forming assays suggested that the combination also 
significantly inhibited self-renewability of MICs. Taken together, the data suggest that combining 
GSI and ABT-737 is a promising treatment strategy for melanoma that targets MIC survival and 
self-renewability and is worthy of further investigation.    
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Discrimination of dysplastic nevi from common melanocytic nevi by cellular and molecular 
criteria
H Mitsui,1 F Kiecker,2 A Shemer,3 MV Cannizzaro,1,4 CQ Wang,1 N Gulati,1 H Ohmatsu,1 
KR Shah,5 P Gilleaudeau,1 M Sullivan-Whalen,1 I Cueto,1 NS McNutt,1 M Suárez-Fariñas1,6 
and JG Krueger1 1 Laboratory of Investigative Dermatology, The Rockefeller University, New 
York, NY, 2 Department of Dermatology and Allergy, Charité Universitätsmedizin Berlin, 
Berlin, Germany, 3 Department of Dermatology, Tel-Hashomer Medical Center, Ramat-Gan, 
Israel, 4 Department of Dermatology, University of Rome Tor Vergata, Rome, Italy, 5 Texas 
Dermatology Associates, Baylor University Medical Center, Dallas, TX and 6 Center for 
Clinical and Translational Science, The Rockefeller University, New York, NY
Dysplastic nevi (DNs), also known as Clark’s nevi or atypical moles, are distinguished from com-
mon melanocytic nevi (CMNs) by variegation in pigmentation and clinical appearance, as well 
as differences in tissue patterning. However, cellular and molecular differences between DNs 
and CMNs are not completely understood. Using cDNA microarray, quantitative RT-PCR, and 
immunohistochemistry, we molecularly characterized DNs and analyzed the difference between 
DNs and CMNs. 111 probesets (91 annotated genes, FCH>2.0 and FDR<0.25) were differentially 
expressed between the two lesions. An unexpected finding in DNs was altered differentiation and 
activation of epidermal keratinocytes with increased expression of hair follicle related molecules 
(KRT25, TCHH, RNASE7) and inflammation related molecules (S100A7, S100A8) at both genomic 
and protein levels. The immune microenvironment of DNs was characterized by an increase of 
Th1 (IFNγ) and Th2 (IL13) cytokines as well as an up-regulation of OSM and CXCL1. DUSP3 which 
regulates cellular senescence, was identified as one of the disease discriminative genes between DNs 
and CMNs by three independent statistical approaches and its altered expression was confirmed 
by immunohistochemistry. The molecular and cellular changes in which the epidermal-melanin 
unit undergoes follicular differentiation as well as up-regulation of defined cytokines could drive 
complex immune, epidermal, and pigmentary alterations.    
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Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma
L Yue,1,2 Z Huang,1,2 S Fong,2 S Leong,3 JG Jakowatz,4 A Charruyer,1,2 ML Wei1,2 and 
R Ghadially1,2 1 Dermatology, University California San Francisco, San Francisco, CA, 2 
Dermatology, VAMC, San Francisco, CA, 3 Oncology, California Pacific Medical Center, San 
Francisco, CA and 4 Dermatology, University of California Irvine, Irvine, CA
In previous studies, cells with aldehyde dehydrogenase 1 (ALDH1) activity from human melanomas 
were more tumorigenic than cells without ALDH1 activity. We examined whether ALDH1 inhibition 
(diethylaminobenzaldehyde) in combination with chemotherapy would make ALDH1+ cells more 
responsive to chemotherapy and thus reduce the number of residual tumorigenic cells. The number 
of tumorigenic cells post-chemotherapy was not changed in dacarbazine treated vs. vehicle treated 
melanoma xenografts, but was decreased in diethylaminobenzaldehyde/ dacarbazine treated vs. 
vehicle treated melanoma xenografts (21x10-5±14x10-5 and 6.3 x10-5±3.5 x10-5 % of total cells 
vs. 24 x10-5±16 x10-5, NS and P=0.05, respectively). In vitro, ALDH1 inhibition in conjunction 
with chemotherapy resulted in increased apoptosis preferentially in ALDH1+ cells. The effect of 
decreasing ALDH1A1 expression by the use of shRNA on the growth of human melanoma xeno-
grafts was then examined. Average time to first palpability of melanomas derived from ALDH1A1 
depleted cells was longer than that for melanomas derived from control cells (5.5±0.2 vs.1.0±0 
weeks, P<0.0001). Melanomas derived from ALDH1A1 depleted cells were of less weight than those 
from control cells (0.09±0.01g vs. 0.49±0.07g, P<0.0001). Finally, injection of ALDH1A1 depleted 
cells into the murine lateral tail vein resulted in decreased numbers of metastases (89±50 vs. 12±12, 
P=0.0004) and decreased metastatic tumor burden (weight of lung and metastases 0.59±0.02g vs. 
1.09±0.05g, P=0.01). Thus combinatorial chemotherapy using ALDH1 inhibition and dacarbazine 
reduced the frequency of residual tumorigenic cells post-therapy and ALDH1A1 depletion had 
dramatic effects on melanoma growth and metastasis. These findings support a potential role for 
ALDH1 inhibition as a therapeutic strategy to target the most aggressive melanoma cells.    
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Melasma in Mexican women. A prevalence study of anxiety, depression and its impact on 
quality of life
A Rodríguez-Arámbula,1,2 JP Castanedo-Cázares,1,2 D Hernández-Blanco1,2 and B Torres-
Alvarez1,2 1 Dermatology, Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosi, 
Mexico and 2 Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico
Melasma is an acquired idiopathic pigmentary disorder characterized by chronic and relapsing 
facial hyperpigmentation that poses a substancial emotional and psychosocial burden on patients. 
Women from varied racial backgrounds, socioeconomic statuses and skin types are affected but it 
is most frequent in Hispanic women with phototypes III to V of Fitzpatrick. Multiple studies have 
demonstrated that this entity affects social function, labor productivity, and self esteem. However, 
the prevalence of anxiety and depression and its impact on quality of life is unknown. The aims 
of this study were to determine the prevalence of anxiety and depression in Mexican women 
with melasma using the Hospital Anxiety and Depression Scale (HADS) and to evaluate the rela-
tion between these psychiatric disorders with severity of disease, and social demographic factors. 
One hundred female patients with melasma were enrolled in the study. Mean age was 45 years. 
Phototypes were IV (83%), and V (13%). Mean duration of disease was 6 years. Disease severity 
was estimated by Melasma Area and Severity Index (MASI) and ranged from 3.9 to 48 (mean 32). 
Demographic information was collected. Pearson correlation coefficient (r) was assessed and the 
statistical significance was set at p<0.05. We found a prevalence of 62% of anxiety and 53% of 
depression. A positive relation between MASI scores and anxiety was noted (r=0.22, p=0.01). No 
relation was observed between MASI scores and depression. There were no statistically significant 
differences in duration of disease, previous treatments, or grade-level education with anxiety or 
depression. The results indicated a significant prevalence of anxiety and depression in melasma and 
a direct relation between severity of disease and anxiety. Dermatologists are in a unique position 
for screening this psychiatric comorbidities, and thus be able to provide the patient with optimal 
care and aid in improving their quality of life.    
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Induction of endoplasmic reticulum stress as a strategy for melanoma therapy
DS Hill,1,2 KA Beaumont,1 A Anfosso,1 P Lovat,2 W Weninger1,3,4 and NK Haass1,3,5 1 
Centenary Institute, Sydney, NSW, Australia, 2 Dermatological Sciences, Newcastle 
University, Newcastle upon Tyne, United Kingdom, 3 Discipline of Dermatology, University 
of Sydney, Sydney, NSW, Australia, 4 Department of Dermatology, Royal Prince Alfred 
Hospital, Sydney, NSW, Australia and 5 The University of Queensland Diamantina Institute, 
Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia
We have shown that melanomas are composed of differentially cycling tumour cells in a subcom-
partment-specific distribution, which may result in differential sensitivity to apoptosis. Further, 
targeting the endoplasmic reticulum (ER) with fenretinide (synthetic retinoid) or bortezomib (26S 
proteasome inhibitor) induces cell cycle arrest and apoptosis of metastatic melanoma cells in vitro 
and in vivo. This study aims (1) to investigate the effect of ER stress-inducing drugs on the dynamics 
of cell division and cell death of individual melanoma cells within the tumour microenvironment, 
and (2) to develop combination strategies that increase the efficacy of ER stress-inducing agents for 
the treatment of melanoma. We utilized the fluorescent ubiquitination-based cell cycle indicator 
(FUCCI), which facilitates real-time cell cycle tracking. We utilised the F-XBP1ΔDBD-venus reporter 
construct, which labels the cytoplasm in response to ER stress. We show that bortezomib-induced 
ER stress, delayed cell cycle progression, and combination with fenretinide increased cell death and 
caused tumor regression in our 3D melanoma model. While the selective BRAF-inhibitor vemu-
rafenib induced G1 arrest, bortezomib induced G1- and G2 arrest, but preferentially killed G2-phase 
cells. Temozolomide enhanced the cytotoxic effect of bortezomib. However, MEK inhibitors blocked 
the effect of bortezomib in all melanoma cells, as did BRAF inhibitors in BRAF mutant cells. Our 
data suggest that bortezomib combined with fenretinide or temozolamide is a therapeutic strategy 
worth exploring for the treatment of BRAF-inhibitor insensitive or resistant melanoma. Importantly, 
melanoma cells in G1 are protected from the cytotoxic effect of bortezomib, which excludes MAPK 
inhibitors as combination partners.    
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Hybrid-featuring melanoma CAD for self-diagnosis
C Shie,1 F Fan1 and Y Liao2 1 HTC Corporation, New Taipei City, Taiwan and 2 College of 
Medicine, National Taiwan University Hospital, Taipei, Taiwan
Early diagnosis of cutaneous melanoma is very essential for the fight against cancer, through it takes 
lots of resource including money and time for everyone to routinely check the nevi. The ABCD 
rule, the Menzies’ scoring method, and the seven-point checklist are well known dermoscopic 
algorithms to diagnose melanoma, but all of them need professional training and sometimes it’s 
easy to confuse with other pigmented tumors such as seborrheic keratosis and basal cell carcinoma. 
Here we propose a novel system called “Hybrid-featuring Melanoma CAD” for everyone to do the 
self-diagnosis at home. The hybrid-featuring system utilizes the multiple color channels information 
to segment the lesion and followed by feature extraction of the geometry, the color and the texture 
from the lesion. The geometric and color features are based on the “ABCD” concept but the accuracy 
is much better when dealing with melanoma, seborrheic keratosis, and basal cell carcinoma at the 
same time. For personal use, our system provides great cost-saving and high privacy for everyone. 
In conventional CAD for melanoma, people use perfect images to develop the system and it would 
fail due to imperfect images taken by the users. We develop and optimize the decision tree to pre-
vent this error. The performance of the system is assessed using the area under curve (AUC) of the 
receiver operating characteristic (ROC) curve. The classification permitted to have an AUC score 
of 89.6%. In conclusion, we develop a robust and auto-detection system for melanoma. We aim to 
help to detect the melanoma as early as possible for the welfare of the people.    
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Regions of birth and residence are predictors of vitiligo extent
J Silverberg,1 M Reja2 and NB Silverberg2 1 Dermatology, Northwestern University, Chicago, 
IL and 2 Dermatology, St. Luke’s-Roosevelt Hospital Center, New York, NY
Little is known about population-based risk factors and regional differences for vitiligo. We sought 
to determine the impact of place of birth and residence on vitiligo extent. We conducted an interna-
tional online-survey of 2,786 adults (72.2% resided in the US) with a history of physician-diagnosed 
vitiligo. Vitiligo subjects who were born outside the US had lower odds of BSA>25%, even after 
controlling for race/ethnicity, sex and current age (logistic regression; adjusted odds ratio [95% 
confidence interval]: 0.62 [0.53–0.74]). Birthplace in all continents had lower odds of BSA>25% 
than those from North America. Adults born outside the US had less BSA whether they resided 
inside (0.58 [0.41–0.81]) or outside the US (0.60 [0.48–0.76]). The prevalence of BSA>25% varied 
greatly by state of residence (range: 27.3% in Maryland; 100% in North Dakota, South Dakota and 
Wyoming) (Global Moran index=0.01, P<0.0001; G-statistic=0.98, P<0.0001). Spatial regression 
models that controlled for the regional variation were constructed and confirmed that US birthplace 
was associated with lower odds of BSA>25% (0.61 [0.45–0.83]) but not race/ethnicity. These results 
suggest there are previously unrecognized environmental factors that drive vitiligo extent/severity. 
Further studies are needed to confirm these early findings and identify such risk factors.    
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CD271 expression is inversely correlated with melanoma aggressiveness in 3-dimensional 
tumor models
A Saltari, F Truzzi, R Lotti, P Morandi, T Petrachi, A Marconi and C Pincelli University of 
Modena and Reggio Emilia, Modena, Italy
Melanoma, the most aggressive form of skin cancer, is characterized by a poor prognosis and few 
therapeutic options for the more advanced stages. Given that alterations in neurotrophin signal 
play a critical role in human cancers, we studied the role of the neurotrophin receptor CD271 in 
the progression of melanoma. Cell lines derived from primary (WM115, SkMel28, WM793B) and 
metastatic melanomas (WM266-4 and 1205Lu) were grown by using 3dimentional (3D) models 
such as spheroids and skin equivalents. First, the validation of the 3D spheroids model through 
proliferation and invasion assays (collagen I invasion), showed a significant correlation between 
proliferation/invasion of spheroids and progression stage of the tumor cell lines. For example, the 
number of invading cells in 1205Lu was significantly higher than in WM115 cell lines (p<0.01). 
CD271 expression was high in poorly aggressive primary melanomas (98% in the least aggressive 
WM115 cell line) while it was significantly less expressed in more aggressive cell lines, such as 
SkMel28 and 1205Lu (45% and 20 %, respectevely), as shown by flow cytometry. Results were con-
firmed by Western blotting and confocal microscopy. Similarly, CD271 was found highly expressed 
in 3D skin equivalents derived from WM115 and tended to disappear in reconstructs from the 
most aggressive 1205Lu cell line. When spheroids were implanted into collagen I, CD271+ cells 
were confined to the body of the sphere, while CD271− were more invasive (p<0,01), as shown 
by immunohistochemistry. Moreover, CD271+ and CD271− melanoma cells were sorted from 
SKMel28. Spheroids obtained from CD271− cells showed higher proliferative and invasion abilities 
if compared to spheroids from CD271+ cells (p<0,01). Finally, siRNA-CD271 transfection resulted 
in the acquisition of a more aggressive behavior with an increase in growth (p<0,01) and invasion 
ability (p<0,05). These results indicate that CD271 plays a crucial role in melanoma progression 
and could be used as a prognostic factor.    
726
The NFkB target gene miR146a is highly expressed in melanoma and regulates melanoma 
growth
AL Samuels,1 T Bashar,3 MS Ning,1 KA Clay,1 G LeBras,2 H Loomans,2 CD Andl2 and 
T Andl1 1 Medicine, Vanderbilt University, Nashville, TN, 2 Surgery, Vanderbilt University, 
Nashville, TN and 3 Medicine, Meharry Medical College, Nashville, TN
microRNAs are promising diagnostic tools in cancer biology due to their tissue specificity, resistance 
to degradation and ease of detection in tissues and serum. They have been intensively studied in 
melanoma samples and cell lines but no clear picture of their role in this tumor has emerged so 
far. Our goal was to identify microRNAs that are specific for melanoma and distinguish this tumor 
easily from other skin cancers with the long term goal to obtain a set of microRNAs that can be used 
to test tissue samples or serum for diagnostic and therapy monitoring purposes. To determine the 
specific microRNA profile of squamous, basal, Merkel cell carcinoma and melanomas we screened 
6 samples using Illumina high-throughput small RNA sequencing. miR146a distinguished melanoma 
samples from other skin cancers and was highly expressed in melanoma cell lines. Inhibition of miR-
146a in the melanoma cell line HS294T resulted in diminished growth. While miR-146a regulated 
the expression of predicted conserved target genes LFNG, RABGAP1 and ZNF532, we could not 
detect inhibition of NFkB signaling by miR-146a, a pathway tightly linked to miR-146a activation. 
In addition, treatment of HS294T cells with potential NFkB signaling inhibitors bortezomid, oubain, 
resveratrol or cantharidin did not result in significant changes in miR-146a expression levels. This 
indicates that miR-146a may play a role in melanoma outside of its well-established role in NFkB 
signaling. However, the identification of the Notch signaling regulator lunatic fringe (LFNG) as a 
putative miR-146a target gene offers an alternative explanation. We hypothesize that LFNG may 
be the main contributor to the observed pro-growth effects mediated by miR-146a as we observe 
its repression by miR-146a in melanoma. Future studies will have to explore the role of miR-46a 
as a melanoma biomarker, for example in serum samples of patients, and in Notch signaling.   
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NLRP1 is involved in melanoma tumorigenesis and temozolomide chemoresistance
Z Zhai,1 W Liu,1 M Kaur,1 Y Luo,1 DA Norris,1,2 CA Dinarello,3 RA Spritz3 and M Fujita1,2 1 
Dermatology, University of Colorado Denver SOM, Aurora, CO, 2 Denver Veterans Affairs 
Medical Center, Denver, CO and 3 Medicine, University of Colorado Denver SOM, Aurora, 
CO
IL-1β is a key inflammatory cytokine responsible for inflammation-promoted melanoma tumori-
genesis. The processing of bioactive IL-1β depends on caspase-1 activation which is regulated by 
inflammasome, including NLRP1 and NLRP3. Our previous studies have demonstrated that NLRP3 
is essential for IL-1β-mediated autoinflammation in melanoma tumorigenesis. The purpose of this 
study was to further assess the NLRP1 regulation of melanoma tumorigenesis. NLRP1 is present 
in both primary and metastatic melanomas. NLRP1 knockdown with shRNA in WM35 primary 
melanoma cells had little effects on IL-1β secretion, but resulted in increased proliferation in vitro 
and tumorigenesis in vivo in nude mice. On the contrary, silencing NLRP1 in 1205Lu metastatic 
melanoma cells led to decreased proliferation, IL-1β secretion, and NF-κB activity in vitro as well 
as slower tumor formation in vivo. These data suggest that NLRP1 has a dual role; it suppresses 
tumorigenesis in primary melanoma, but promotes tumorigenesis in metastatic melanoma. The 
differential regulation of the two stages of melanoma by NLRP1 may be partially related to its dis-
tinct subcellular localization; NLRP1 exhibited nuclear localization in WM35 and WM115 cells, 
but was predominately expressed in perinuclear region in 1205Lu and HS294T cells. In addition, 
we examined the involvement of NLRP1 in the chemoresistance to temozolomide (TMZ), a drug 
for metastatic melanoma. TMZ treatment of 1205Lu led to increased NLRP1 expression, caspase-1 
activity, IKKα/β phosphorylation, and IL-1β synthesis and secretion. However, silencing NLRP1 
attenuated TMZ-induced IL-1β synthesis and secretion. Interestingly, TMZ and NLRP1 knockdown 
showed a synergistic inhibition of 1205Lu proliferation, suggesting that NLRP1 is not only involved 
in melanoma tumorigenesis, but plays a role in TMZ chemoresistance. Our data may help develop 
NLRP1-based therapeutics for human melanoma.    
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Methods of generating single cell suspensions from tumor tissues influence the frequency 
of tumor-initiating cells
Y Luo,1 S Liu,1 LK Kutty,1 JJ Arcaroli,2 SE Robinson,2 WA Robinson,2 DA Norris,1,3 
WA Messersmith2 and M Fujita1,3 1 Dermatology, University of Colorado Denver, Aurora, 
CO, 2 Medicine, University of Colorado Denver, Aurora, CO and 3 Denver Veterans Affairs 
Medical Center, Denver, CO
The tumorigenic potential of single tumor cells is a crucial factor in human cancer because of 
its therapeutic implications. Conflicting reports on the frequency of tumor initiating cells (TICs) 
in human melanoma suggest that variations in tumor digestion, sorting and xenotransplantation 
protocols may be the cause of this discrepancy. In the current study, we examined the effects of 
tumor digestion protocols on TIC frequency using patient-derived tumor xenografts (PDTX) from 
melanoma, colon and pancreatic cancers. Single cell suspensions were generated from PDTX 
tumors by eight different digestion methods: collagenase I or IV; shorter (20 min) or longer (2 h) 
digestion with collagenase; and with or without trypsin. The type of collagenase did not show 
significant effect on the yield of viable melanoma cells. However, 20 min digestion resulted in the 
decrease in viable melanoma cell counts (-59%; P<0.01) compared to 2 h digestion, and addition 
of trypsin further reduced the yield by 44% (P<0.05). The effect of 20 min digestion on cell counts 
was also observed in human colon (-40%) and pancreatic (-44%; P<0.05) cancer. ALDH+ human 
cells were enriched with 20 min digestion in melanoma (3.6-fold; P<0.05) and colon cancer cells 
(4.7-fold; P<0.05). Trypsin addition also enriched ALDH+ melanoma cells (2.1-fold; P<0.01). When 
melanoma cells were implanted with high-protein matrigel into NOD/SCID/IL-2Rγc-null mice, the 
TIC frequency was higher (P<0.05) in cells generated from 20 min digestion with trypsin (1 in 10) 
compared to those generated from 2 h digestion without trypsin (1 in 73). These results reveal the 
heterogeneous tumorigenic capacity of human cancers, and indicate that some methods used to 
isolate cells from tumor tissues may enrich tumorigenic cells.    
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The effect of combination therapies of thioridazine and vemurafenib on melanoma
Y Tameze,1 S Degan,2 Q Zhang,1 J Jin,1 J Wilson,2 C Gainey,2 W Warren2 and JY Zhang1 1 
Dermatology, Duke University, Durham, NC and 2 Chemistry, Duke University, Durham, 
NC
Despite recent advances in BRAF-targeted therapies, melanoma continues to be one of the most 
deadly forms of cancer. We have recently found that the mucosa associated lymphoid tissue lym-
phoma translocation gene 1 (MALT1) is expressed at an increased level in metastatic melanoma cells. 
The goal of this study is to explore the effect of combination therapies containing the oncogenic 
BRAF600E-inhibitor vemurafenib and the dopamine antagonist thioridazine, an agent that has been 
shown to inhibit MALT1 for effective treatment of aggressive B-cell lymphoma. We used the con-
ditional Tyr-Cre.BRAFCa/+.Ptenfl/fl mouse genetic model and the subcutaneous human melanoma 
model generated on immunodeficient NSG mice. In the genetic mouse model, we observed that 
melanomas developed on animals treated with vemurafenib alone or together with thioridazine 
exhibited slower growth kinetics accompanied with clinical and pumb-probe microscopic evidence 
of regression, and appeared generally darker than those of control tumors. Immunostaining for 
Ki-67 and the cleaved caspase 3 revealed markedly decreased cell proliferation and increased cell 
apoptosis in treated tumors. A reduced tumor growth kinetic was also observed in the subcutaneous 
human melanoma model during the initial 10-day treatment with vemurafenib and thioridazine as 
compared to vemurafenib alone. Nevertheless, tumors regained growth after the initial stall irre-
spective of the treatment strategies examined. Our findings suggest that thioridazine may improve 
the clinical effect of vemurafenib for a limited period of time. We are currently testing the effect of a 
higher dosing of thiorizadine for the combination treatments and examining the role of melanocyte 
differentiation program in chemoresistance.    
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Fisetin enhances the therapeutic efficacy of sorafenib in BRAF-mutated human melanoma 
cells
HC Pal, RD Baxter, J Agarwal, LR Strickland, CA Elmets and F Afaq Dermatology, University 
of Alabama at Birmingham, Birmingham, AL
Melanoma, the most aggressive form of skin cancer, is responsible for approximately 75% of skin 
cancer-related deaths. In melanoma, the BRAF-MEK-ERK (MAPK) and PI3K-AKT-mTOR signaling 
pathways are constitutively activated. These pathways play a pivotal role in cell proliferation, sur-
vival and tumorigenesis. A combination of compounds that lead to an optimal blockade of these 
critical signaling pathways may provide an effective strategy for prevention of melanoma. Fisetin, 
a phytochemical present in fruits and vegetables, possesses anti-proliferative and pro-apoptotic 
activities. Earlier, we showed that fisetin inhibits PI3K/AKT and mTOR signaling pathways. In this 
study, we investigated the effect of fisetin and sorafenib (an RAF inhibitor) alone and in combination 
on cell proliferation, apoptosis and tumor growth. We found that combination (fisetin + sorafenib) 
treatment more effectively reduced the growth of BRAF-mutated human melanoma cells (A375, 
SK-MEL-28 and RPMI-7951) at lower doses when compared to individual agents. In addition, 
combination treatment resulted in enhanced (i) apoptosis, (ii) cleavage of caspase-3 and PARP, (iii) 
expression of Bax and Bak, (iv) inhibition of Bcl2 and Mcl-1, and (v) inhibition of expression of 
PI3K, phosphorylation of MEK1/2, ERK1/2, AKT and mTOR. In athymic nude mice subcutaneously 
implanted with melanoma cells (A375 and SK-MEL-28), we found that combination therapy (fise-
tin + sorafenib) resulted in greater reduction of tumor cell growth when compared to individual 
agents. Furthermore, combination therapy was more effective than treatment with the individual 
agents in: (i) inhibiting markers of proliferation (PCNA and Ki67), (ii) induction of apoptosis, and 
(iii) inhibition of MAPK and PI3K-AKT-mTOR signaling pathways in tumors of athymic nude mice 
implanted with BRAF-mutated melanoma cells. These data suggest that simultaneous inhibition of 
both these signaling pathways using combination of fisetin and sorafenib may serve as a therapeutic 
option for the management of melanoma.    
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Inhibition of HDAC3 accelerates autophagy to induce melanoma cell death
H Wilson, A Velez, J Wu, J Wilson, AS Paller and X Wang Dermatology, Northwestern 
University, Chicago, IL
Although non-specific HDAC inhibitors have shown early promise in clinical trials in preventing 
melanoma progression, little is known about the role of histone deacetylases (HDACs) in mela-
noma. We have previously found that specific inhibition of HDAC3 reduces ganglioside GM3 
deacetylation to prevent activation of PI3K/Akt and p70S6 kinase signaling, thereby inhibiting 
melanoma growth and inducing cell death. We hypothesized that HDAC3 inhibition induces mel-
anoma death through both caspase-dependent apoptosis and caspase-independent autophagy. 
Using immunohistochemistry, qRT-PCR and western blot, we found that increased expression 
and cellular distribution of HDAC3 correlates with melanoma metastasis both in vivo and in vitro. 
When HDAC3 function was suppressed by a small molecule inhibitor (MS-275, specific inhibitor 
of the class I HDACs), the percentage of “dead cells” was increased by 4-fold, correlating with 
a 10-fold increase in caspase-3 activation (p<0.001) and a 4-fold reduction in Bcl-2 expression 
(p<0.01). Importantly, targeted reduction of HDAC3 expression, rather than other class I HDACs 
(HDAC1/2), also led to a 5-fold increase in expression of beclin1 (p<0.001) and a 3-fold increase 
in the expression of LC3 (p<0.01), leading to melanoma cell autophagy. Inhibition of autophagy 
with chloroquine or caspase-3 with Z-DEVD-FMK reduced the death of metastatic melanoma cells 
induced by HDAC3 inhibition (p<0.01), demonstrating that both caspase-independent autophagy 
and caspase-dependent apoptosis participate in HDAC3 inhibition induced melanoma cell death. 
Although autophagy is essential for survival normal cells in a stress environment, autophagy’s impact 
on cancer progression and on the efficacy of cancer therapeutics is uncertain. Results from our study 
indicate that specific inhibition of HADC3, a promising target for treating metastatic melanoma, 
leads to cell death via induction of both autophagy and apoptosis.    
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Inhibiting notch signaling pathway with γ-secretase inhibitor (GSI) induces cellular senes-
cence in melanoma cells
G Zhu, C Li and T Gao Dermatology, Xijing Hospital, Fourth Military Medical University, 
Xi’an, China
Background Cellular senescence is believed to be of great potential in melanoma treatments. Since 
Notch pathway has been proven to be an important regulator of cellular senescence, it leads us to 
a hypothesis that its activation in melanoma may play a role in senescence escape. Accordingly, 
blocking Notch pathway may contribute to the inhibition of melanoma development via therapy- 
induced senescence. Methods We use immunohistological staining to identify the different activa-
tion of Notch in melanoma and nevi lesions. In addition, we used WM35 and 451Lu melanoma 
cell lines, which derived from primary and metastatic phases respectively. SA-β-GAL staining and 
cell cycle profile were used to identify the senescence phenotypes after GSI treatment. Real- Time 
PCR and Western Blot were used to detect the change of cell cycle G1 phase molecules expression 
including, cyclin D1, cyclin E1, cyclin E2, CDK2, CDK4, CDK6, p21, p27 and pRb in response to 
GSI treatment. Results: The melanoma lesions showed higher Notch1 ummunohistological stain-
ing positive rate(4/5) than nevi lesions(1/5). Inhibition of Notch signalling with GSI induced cell 
cycle arrest and senescence phenotypes in melanoma cell lines. Real-Time PCR and Western Blot 
found that key effectors and regulators of G1 phase changed significantly in response to GSI treat-
ment, which may partially explain the mechanism of the GSI- induced senescence in melanoma 
cells. Conclusion: Our findings offered new clues to the role of Notch signaling in the progress of 
melanoma in aspect of senescence escape and may lead to the identification of novel targets for 
therapeutic interventions.    
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IMP-3 promotes tumor invasion and predicts poor prognosis in acral lentiginous melanomas
S Jee,1,4 Y Sheen,1,4 C Yeh,1 P Chen,1 M Kuo2,3 and C Chu1,4 1 Department of Dermatology, 
College of Medicine, National Taiwan University, Taipei, Taiwan, 2 Graduate Institute of 
Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan, 3 Institute of 
Biochemical Sciences, College of Life Science, National Taiwan University, Taipei, Taiwan 
and 4 Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan
Insulin-like growth factor-II messenger RNA (mRNA)-binding protein-3 (IMP-3) has been found to be 
a novel progression marker in malignant melanoma of Caucasians. Samples from a total of 97 Han 
Chinese patients with primary cutaneous melanoma were collected and analyzed. Acral lentiginous 
melanoma (ALM) was the most common subtype (74/97, 76.3%), followed by nodular melanoma 
(12/97, 12.4%), superficial spreading melanoma (8/97, 8.2%), and lentigo maligna melanoma 
(3/97, 3.1%). To examine the clinical significance of melanoma IMP-3 expression, the correlation 
between important clinico-pathologic variables and IMP-3 expression was analyzed using logis-
tic regression. IMP-3 expression was significantly associated with the ALM subtype (OR=3.93, 
95%CI=1.11-13.94; P = .0034) and with the stage III/IV melanoma (OR=5.40, 95%CI=1.17-24.87; 
P = .031), but not with age, sex, ulceration, lymph node metastasis, or tumor thickness. Univariate 
analysis using a Cox regression model showed that lymph node metastasis, advanced melanoma 
stage, and IMP-3 expression were predictive of poor outcomes. Following Kaplan-Meier analysis, 
ALM patients who were positive for IMP-3 expression had significantly reduced overall survival 
than those ALM patients who were negative for IMP-3 expression (log-rank test, P = .0028). It was 
also confirmed that over-expression of IMP-3 in MeWo cells enhanced migration, invasion and 
metastasis of melanoma cells, while knock-down of IMP-3 inhibited the migratory/invasive abilities 
of A2058 cells. In summary, IMP-3 may serve as a poor prognostic factor for melanoma, especially 
ALM, and might be a future therapeutic target for ALM treatment.    
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Effect of 3oxo-glycyrrhetinic acid on tyrosinase and trp1 protein in normal human melanocytes
A Thiessen, L Terstegen, F Stäb, H Wenck, L Kolbe and A Mahns Front End Innovation, 
Applied Skin Biology, Beiersdorf AG, Hamburg, Germany
Glycyrrhetinic acid, a component in Licorice root extract, is well known for its anti-diabetic, anti-ox-
idant and anti-tumorigenic properties. Here, we investigated the stimulating effect of 3oxo-Glycyr-
rhetinic acid (3oxo-GA), a derivative of Glycyrrhetinic acid, on melanin synthesis in normal human 
melanocytes (NHM). 3oxo-GA stimulates not only protein level of Tyrosinase (TYR) but also of its 
chaperone Tyrosinase-related protein-1 (TRP-1). Knock down of TRP-1 had no effect on 3oxo-GA 
mediated increase of TYR protein level, excluding TRP-1 as the driver for TYR induction and favoring 
a rather independent effect of 3oxo-GA on both proteins. Both, the observation that 3oxo-GA has no 
effect on Tyr-mRNA level and the fact that two different approaches to inhibit TYR de novo protein 
synthesis were not able to abrogate the effect of 3oxo-GA on the induction of the melanogenic key 
enzyme Tyrosinase, support the hypothesis that 3oxo-GA stimulates melanogenesis via a posttrans-
lational mechanism. Furthermore, glycosylation analysis revealed an accumulation of mainly the 
mature form of TYR and more interestingly, the impaired TYR processing due to Resveratrol treatment 
could be balanced by 3oxo-GA. Taken together, 3oxo-GA stimulates melanogenesis in NHM via 
a posttranslational mechanism and we hypothesize a promoting effect on TYR protein processing.   
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 Diclofenac induces expression of TNF-related apoptosis-inducing ligand in adaptive and 
innate immune cells
MI Vazquez-Strauss and G Stingl Department of Dermatology, Division of Immunology, 
Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria
Evidence exists in both humans and experimental animals that induction of lytic molecules such 
as TNF-related apoptosis inducing-ligand (TRAIL) (e.g. by Imiquimod) endows immune cells with 
cytotoxic properties against cancer cells. To a varying extent, this is also true for melanoma. In 
order to understand the differences in TRAIL susceptibility of different melanoma cells, we tested 
the expression of 91 apoptosis-related genes by a qPCR array and compared a highly-susceptible 
(WM793) vs. two resistant (WM983A and 1205Lu) melanoma cell lines. Results obtained showed 
that both resistant cell lines expressed higher constitutive levels of the anti-apoptotic molecule 
BCL2A1 mRNA than the susceptible cell line. Similar to what has been reported for squamous cell 
carcinoma, we observed that both WM983A and 1205Lu cell lines showed a higher susceptibility 
to TRAIL-induced apoptosis when pretreated with diclofenac (diclofenac+TRAIL vs. control+TRAIL; 
WM983A: 71.70% vs. 27.00%; 1205Lu: 23.98% vs. 2.28% apoptotic cells, respectively). This 
phenomenon was associated with an upregulation, by diclofenac, of the proapoptotic molecules 
caspases 5 and 10, NOXA, CYCS, TRAILR2, DDIT3 and XBP1 as assessed by qPCR array. Surpris-
ingly enough, we also found that overnight stimulation of PBMCs with diclofenac results in the 
enhanced expression of TRAIL by different immune cell subpopulations (monocytes, mDC, pDC, T 
cells, NK cells) in a magnitude similar to that observed with Imiquimod. These results suggest that 
the antitumoral properties of diclofenac are not only related to its direct effects on tumor cells but 
also to its capacity to promote a cytotoxic effector phenotype in immune cells.    
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miR-638 promotes melanoma metastasis and is repressed by transcription factor AP2-alpha
A Bhattacharya,1 U Schmitz,2 Y Raatz,1 M Schönherr,1 T Kottek,1 M Schauer,1 S Franz,1 
A Saalbach,1 U Anderegg,1 O Wolkenhauer,2 D Schadendorf,4 JC Simon,1 T Magin,3 J Vera2 
and M Kunz1 1 Department of Dermatology, Venereology and Allergology, University 
of Leipzig, Leipzig, Germany, 2 Institute of Informatics, Department of Systems Biology 
and Bioinformatics, University of Rostock, Rostock, Germany, 3 Translational Centre for 
Regenerative Medicine (TRM), Division of Cell and  Developmental Biology, University of 
Leipzig, Leipzig, Germany and 4 Department of Dermatology, Venereology and Allergology, 
University Hospital Essen, Essen, Germany
In a recent study involving miRNA profiling in melanoma, we identified miR-638 to be overex-
pressed in metastatic stages of melanoma. Depletion of endogenous miR-638 in melanoma cells 
induced significant levels of autophagy and p53 mediated apoptosis. Overexpression of miR-638 
significantly enhanced proliferation, clonogenicity, migration and anchorage-independent growth 
of melanoma cells under in vitro conditions. In a mouse xenograft model, human melanoma 
cells stably overexpressing miR-638 exhibited significantly higher potential to colonize in lungs as 
compared to non-targeting control expressing cells. Overall these results confirmed the oncogenic 
role of miR-638 in melanoma. Further analysis revealed tumour suppressors like TP53INP2 and 
BTG2 to be targets for miR-638. Using in silico transcription factor analysis and chromatin immu-
noprecipitation (ChIP) experiments, we identified AP2-alpha (TFAP2A gene), a known melanoma 
suppressor, to transcriptionally repress miR-638 in a methylation dependent manner. Furthermore, 
TFAP2A expression levels were significantly suppressed by miR-638, indicating TFAP2A as a target 
for miR-638. These findings provided strong evidence that TFAP2A and miR-638 regulate each other 
through a double-negative feedback mechanism. Taken together, these findings demonstrate that 
miR-638 is an important oncomiR in melanoma and might prove to be a potential targeting option 
in future melanoma therapies.    
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Immunotargeting of established experimental melanoma by chemokine-enhanced DNA 
vaccination
O Igoucheva,1 V Alexeev,1 M Grazzini2 and D Kemp1 1 Dermatology and Cutaneous 
Biology, Jefferson Medical College, Philadelphia, PA and 2 Dermatology, University of 
Florence, Firenze, Italy
DNA vaccines are attractive candidates for tumor immunotherapy. However, the potential of DNA 
vaccines in treating established malignant lesions has yet to be demonstrated. Here we demonstrate 
that transient alteration of either intratumoral or intradermal (ID) chemotactic gradients provide 
a favorable milieu for DNA vaccine-mediated activation of tumor-specific immune response in 
both prophylactic and therapeutic settings. Specifically, we show that priming of established B16 
ID melanoma lesions via forced intratumoral expression of CCL21 boosted DNA vaccination-de-
pendent systemic cytotoxic immune response leading to the regression of tumor nodules. In this 
setting, application of CCL20 was not effective likely due to the engagement of the regulatory T cells. 
However, priming of the skin at DNA vaccine administration sites outside the tumor bed with both 
CCL20 and CCL21 chemokines along with structural modifications of the DNA vaccine significantly 
improved vaccine efficacy. This optimized ID vaccination regimen led to the inhibition of distant 
established melanomas and prolonged tumor-free survival of mice observed in 60% of vaccinated 
animals with complete tumor remission in 30%. These effects were mediated by extranodal priming 
and activation of T cells at vaccine administration sites and progressive accumulation of systemic 
antigen-specific cytotoxic T cells (CTLs) on successive vaccinations. These results underscore the 
potential of chemokine-enhanced DNA vaccination to mount therapeutic immune response against 
established tumors.    
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Misbalanced CXCL12 and CCL5 chemotactic signals may contribute to the onset and pro-
gression of vitiligo
V Alexeev, O Igoucheva, D Kemp and J Lee Dermatology and Cutaneous Biology, Jefferson 
Medical College, Philadelphia, PA
Based on genetic susceptibility studies and clinical observations, generalized non-segmental vit-
iligo (NSV) was recently re-evaluated as an autoimmune disorder. Considering an important role 
of chemokines, small protein molecules that direct trafficking of leukocytes during activation/
maintenance of immune responses, we examined expression of chemokines and their receptors 
in various cutaneous melanocytes. Our analysis revealed a significant up-regulation of CXCL12 
and CCL5 expression in melanocytic cells isolated from vitiligo patients and in post-inflammatory 
pigmentary alteration vitiliginous lesions as compared to melanocytes and skin from normal donors. 
Moreover, our in vivo animal studies showed that melanocyte-derived CXCL12 and CCL5 facilitate 
infiltration of the skin with CD3+ T and CD11c+ antigen presenting cells and preferential targeting 
of chemokine-secreting melanocytes by the adoptively transferred melanocyte-reactive splenocytes 
resulting in development of the vitiligo-like lesions in mice. Considering that chemokines are the 
primary regulators of leukocytes diapedesis and migration to peripheral tissue, we suggested that 
melanocyte-derived CXCL12 and CCL5 may play a critical role in the onset and progression of 
autoimmune vitiligo.    
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Clearance of malignant ascites by interferon-induced senescence
C Boss,1 E Brenner,1 H Braumüller,1 T Wieder,1 S Kayser,2 T Feuchtinger2 and M Röcken1 1 
Department of Dermatology, University of Tübingen, Tübingen, Germany and 2 Children’s 
Hospital, University of Tübingen, Tübingen, Germany
Recent studies showed that tumor immunotherapy is moving from pre-clinical to clinical studies. 
Currently, the therapy focuses on the treatment of patients with advanced metastatic disease. We 
have recently shown that cytokines are capable of paralyzing cancer through induction of senes-
cence in a variety of malignant cells, including primary melanoma cells. To analyze the potential 
effects of the combined action of interferon (IFN) and tumor necrosis factor (TNF) on melanomas, we 
treated a panel of cell lines with these two cytokines. FACS-analysis showed that IFN-gamma and 
TNF can cause apoptosis and a senescence characterizing G0/G1 arrest. In a series of melanomas, 
this cell cycle arrest remained stable for >5 passages after withdrawal of IFN-gamma and TNF, a 
state that defines cellular senescence. Moreover, following stimulation with IFN-gamma and TNF, 
melanoma cells engaged a senescence-associated secretory phenotype with the production of IL-6, 
IL-8, IP-10 and CCL-2. Thus, we could demonstrate that IFN can induce senescence in melanoma 
cell lines in vitro. We could also show senescence induction in melanoma cells in vivo by treating a 
patient with stage IV malignant melanoma with interferon-alpha. The patient had a malignant ascites 
and was therefore bedridden with an ECOG performance status of 4. The tumor board suggested 
a compassionate use treatment with interferon-alpha administered intraperitoneally to enhance 
the life quality for the patient. This treatment cleared the ascites completely and the life quality 
was dramatically enhanced with an ECOG performance status of 1. Ex vivo analyses of the ascites 
confirmed the induction of senescence in the malignant cells during the treatment. Thus, interferon 
can drive human melanomas into senescence in vitro and in vivo, a breakthrough discovery that 
is of great therapeutic relevance.    
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Mucosal melanoma: Incidence at University Hospitals Case Medical Center from 1997-2013
S Patel, K Honda, KD Cooper and MR Gerstenblith Dermatology, University Hospitals Case 
Medical Center, Cleveland, OH
Mucosal melanoma accounts for roughly 1% of all reported melanomas, and studies of somatic 
mutations suggest they are distinct from cutaneous melanomas. Mucosal melanomas, arising within 
the head and neck, anorectum, and gastrointestinal and genital tracts, carry a poor prognosis since 
they are often diagnosed at a late stage. Initially thought to be stable, national data suggest that some 
mucosal melanoma subtypes are increasing in incidence, particularly within certain demographic 
groups. To further characterize mucosal melanoma, we performed a retrospective review to deter-
mine trends in primary mucosal melanoma by subtype according to age, gender, and race from 
1997 to 2013 at University Hospitals Case Medical Center (UHCMC), a tertiary referral center in 
Cleveland, Ohio. Cases were identified using the UHCMC Pathology Database, with additional data 
extracted from medical records. Sixty-nine cases of primary mucosal melanoma were identified from 
1997-2013; 19 were excluded due to missing data. Of the 50 confirmed cases of primary mucosal 
melanoma, 19 (38%) originated in the head and neck, 19 (38%) in the genital tract, 9 (18%) in 
the anorectum, and 3 (6%) in the gastrointestinal tract. There were 9 (47%) women and 10 (53%) 
men with head and neck tumors, 6 (67%) women and 3 (33%) men with anorectal tumors, and 2 
(67%) women and 1 (33%) man with gastrointestinal involvement. All of the tumors that originated 
in the genital tract were in women. The frequency of mucosal melanomas increased in all sites at 
our institution from 1997-2013. Women and men presented at older ages (mean ages in years for 
women and men were 66 and 61, respectively). The mean tumor depth was higher for men (20mm) 
than for women (3mm). Limitations of our study include the small case numbers and the inability 
to include 19 cases due to incomplete data. Furthermore, these findings may not be representative 
of the general patient population since UHCMC is a tertiary referral center.    
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Neuropeptide Y expression in cutaneous melanoma
B Pérez-Tato,1 Y Gilaberte,2 L Nájera,3 ÁNGELES Juarranz4 and S Gonzalez5 1 Dermatology, 
Hospital Universitario de Móstoles, Móstoles, Spain, 2 Dermatology, Hospital de San Jorge, 
Huesca, Spain, 3 Pathology, Hospital de Fuenlabrada, Fuenlabrada, Spain, 4 Biology, 
Universidad Autónoma de Madrid, Madrid, Spain and 5 Dermatology, Memorial Sloan-
Kettering Cancer Center, New York, NY
NPY is the most abundantly expressed peptide of the pancreatic polypeptide family, exhibiting 
pleiotropic physiological actions throughout the body. The role of NPY in cancer in humans has 
not been well characterized, and published results seem controversial. We studied the expression 
of NPY on 79 primary melanomas (23 nodular melanoma, 47 superficial spreading melanoma 
(SSM), 5 lentigo maligna, 3 lentigo maligna melanoma and one acral lentiginous melanoma) by 
immunohistochemistry on formalin-fixe paraffin-embedded tumors. Correlation between its expres-
sion with clinical-pathological parameters (Clark and Breslow levels, E-cadherin, inflammatory 
infiltrates, proliferation) and the clinical outcome was analized. NPY was overexpressed in 25 
melanoma tumours (19 SSM, 3 nodular, 2 lentigo maligna and one acral lentiginous melanoma). 
A significant higher expression of NPY was found on SSM (76%) than nodular melanoma (12%) 
(p= 0.031). Deeper tumors correlated with lower NPY expression (Clark level, p= 0.003; Breslow 
level, p= 0.012). Aditionally, melanomas with low NPY expression correlated with high tumor 
cell proliferation (Ki-67, p=0.034), high density of peritumoral mast cell infiltrates (p= 0.033), 
and lower E-cadherin expression (p=0.031). Low NPY expression in melanomas correlated with 
poor relapse-free (p= 0.008) and lower overall survival (p= 0.004). We did not found statistical 
relationship between NPY and mitotic rate or ulceration. In conclusion, NPY was overexpressed in 
one third of melanomas, mostly in SSM, correlating with low tumor proliferation, lower Clark and 
Breslow levels, presence of adhesion proteins and better outcome. These findings support its role 
as a biomarker of differentiation in melanoma.    
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Sox2 and sox10 expression patterning in melanoma
MT Wan,1,2 H Kakavand,4 MC Mihm,1 RA Scolyer,4 JT Thompson,4 GF Murphy2 and JY Lin1,3 
1 Dermatology, Brigham and Women’s Hospital, Boston, MA, 2 Pathology, Brigham and 
Women’s Hospital, Boston, MA, 3 Melanoma Program, Dana-Farber Cancer Institute, 
Boston, MA and 4 Melanoma Institute Australia, Royal Prince Alfred Hospital, Sydney, NSW, 
Australia
Sox2 and Sox10 are key determinants of neural crest cell development. Both belong to the sex 
determining region-Y HMG-box (SOX) family and share a common high-mobility group domain. 
The diverse functions of Sox2 and Sox10 have been further implicated in melanomagenesis. Sox2 
and Sox10 can promote melanoma invasion in vivo and in vitro (Girouard et al., 2012; Mascarenhas 
et al., 2010) and melanoma proliferation (Laga et al., 2010; Ramgolam et al., 2011). Overexpres-
sion of Sox10 has been noted in melanoma tumors and Sox10 silencing counteracts melanoma 
proliferation and survival in vivo (Shakhova et al., 2012). We analyzed depth-matched paraffin-em-
bedded human nodular (NM) and desmoplastic melanomas (DM) for Sox2 and Sox10 expression. 
DM had predominantly Sox10 expression in ~50% of cells, occurring focally deep in the lesion, 
often extending to subcutaneous fat. Expression pattern of Sox2 and Sox10 was variable in NM 
but demonstrated clear heterogeneity. Sox2-only expressing, Sox10-only expressing and Sox2/10 
co-expressing melanoma cells formed distinct architectural units. Frequently, Sox2-only expressing 
cells were noted near vessels, seen at the invasive edge of the melanoma and were apparent in radial 
growth phase. In one case, a NM was associated with lymph node metastases. The predominant 
melanoma cells found in the lymph node expressed both Sox2 and Sox10. Murine melanoma 
xenografts recapitulate Sox2/10 heterogeneity. A tissue microarray of melanoma progression from 
nevi, to thin and thick melanoma, preliminarily suggests that Sox2 expression is associated with 
increased malignant potential. Traditional analyses utilizing melanoma cell lines often do not take 
into account melanoma heterogeneity. Sox2 and Sox10 immunohistochemical expression may 
serve as a useful biomarker for melanoma. In the future, investigation on the regulation of Sox2 
and Sox10 expression will be performed.    
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P1446A-05: A potent cyclin-dependent kinase inhibitor with preclinical activity in melanoma
DM Miller,1 M Taylor,2 R Kumar,2 K Flaherty,3 S Srinivasa,4 S Buch4 and H Tsao2 1 
Dermatology, Columbia University Medical Center, New York, NY, 2 Dermatology, 
Massachusetts General Hospital, Boston, MA, 3 Division of Hematology/Oncology, 
Massachusetts General Hospital, Boston, MA and 4 Piramal Enterprises Ltd, Mumbai, India
Deregulated cell-cycle control is a major mechanism in melanomagenesis. For example, nearly 
100% of melanomas have a defect in the p16INK4A:cyclin D-CDK4/6:Rb pathway, leading to 
abnormal cell-cycle control and unregulated cellular proliferation. Numerous cyclin-dependent 
kinase inhibitors have shown pre-clinical activity against melanoma, and several are being tested 
in clinical trials. P1446A-05, a potent CDK inhibitor (<100 nM IC50 for Cdk8-C, Cdk9-T, Cdk1-B 
and Cdk4-D1) has shown anti-proliferative activity in a variety of cancer cell lines, including non-
small-cell lung cancer, colorectal carcinoma and prostate cancer. Here we report that P1446A-05 
has significant inhibitory activity in melanoma. In a targeted screen of 18 different melanoma cell 
lines, P1446A-05 demonstrated cytotoxicity with IC50’s in the range of 500nM to 2μM. In light of 
cytotoxicity for unstimulated normal human PBMNCs being > 10 μM (previously published data), 
P1446A-05 shows good selectivity on cancer cells. In cell cycle studies, P1446A-05 induced G2/M 
arrest and increased the sub-G1 population. Apoptosis studies revealed that apoptosis was signifi-
cantly induced in a time and dose-dependent fashion. In addition, P1446A-05 affected regulators 
of both the cell cycle and apoptosis. It inhibited Cdk4-specific phosphorylation (ser780 of retino-
blastoma), induced the tumor suppressor protein p53, and reduced the levels of the anti-apoptotic 
proteins MCL-1 and Survivin, though it did not affect levels of CDK4. The effects on cell-viability 
were not dependent on p53, as siRNA-mediated knockdown of p53 did not alter the IC50 of P1446-
05. On going studies will characterize the efficacy of P1446-05 in vivo. Collectively, these data 
demonstrate that P1446A-05 has preclinical activity against cutaneous melanomas and may have 
therapeutic potential for this deadly disease.    
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A distinct chemokine profile favors the development of metastases in human melanoma
A Soler-Cardona,1,2 C Burger1 and RA Loewe1,2 1 Department of Dermatology, Medical 
University of Vienna, Vienna, Austria and 2 Skin and Endothelium Research Division, 
Medical University of Vienna, Vienna, Austria
Chemokines play an important role in metastasis by contributing to processes such as angiogenesis, 
lymphangiogenesis, tumor-host interaction or tumor cell migration. The comparison of normal skin 
to primary tumor tissue and lymph-node metastases in a spontaneously metastasizing xenotransplan-
tation melanoma mouse model, identified twelve differently regulated chemokines. Quantitative 
assessment of mRNA levels from these chemokines in T1 to T4 melanoma human samples identified 
a clustered pattern of these chemokines. The biological relevance of this chemokine profile could 
be further examined by overexpressing the most highly upregulated chemokine in a metastatic 
melanoma cell line and subsequent injection into the skin of CB17-SCID mice, lead to a more inva-
sive tumor phenotype. Histological analysis identified the increased invasiveness into surrounding 
tissue. A marked increase in neutrophil infiltration, lymph node weight and lung metastasis was 
observed. The tumors exhibited increased lymphangiogenic potential, which together with a favored 
neutrophil-tumor cell interaction could potentially explain the increment in metastasis. A positive 
correlation of our results in human material confirms the relevant and versatile role of chemokines 
during the metastatic process.    
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Narrow band ultraviolet B treatment for human vitiligo induces three distinct populations 
of melanocytes
NB Goldstein,1 MI Koster,1 L Hoaglin,1 SE Robinson,2 WA Robinosn,2 DR Roop,1 DA Norris1 
and SA Birlea1 1 Dermatology, UC Denver, Aurora, CO and 2 Oncology, UC Denver, 
Aurora, CO
We have previously reported that the human hair follicle (HF) in vitiligo contains melanocyte (MC) 
stem cells in the bulge (BG) and regions proximal to the BG, making depigmented vitiligo skin an 
exceptional model to study the emergence of MC stem cells and their progeny in the adult human 
skin. Our goal was to determine the location of precursor and differentiated MC populations during 
vitiligo repigmentation. We studied transverse paraffin skin sections from 4 untreated generalized 
vitiligo (GV) patients and 8 GV patients treated with narrow band UVB (NBUVB) for 3-6 months. 
We examined the interfollicular epidermis (IE) and 3 regions of the hair follicle (HF): infundibulum 
(INF), BG and bulb. Triple immunofluorescence was used, with 2 MC antibodies [either anti-c-KIT 
or anti-DCT combined with anti-PAX3 or anti-tyrosinase (TYR)], and one epithelial cell antibody 
(anti-K14). The MC counts were compared to the total number of cells in the basal epidermis or 
outer root sheath of HF in treated versus untreated patients. NBUVB increased the expression of all 
MC markers in all tested regions, except TYR, which was absent in the BG. A significant increase in 
expression of all MC markers (P<0.05) was only found in the treated IE and INF, where co-expression 
with proliferation marker Ki67 was also noted. We identified 3 distinct populations of MC appear-
ing during NBUVB treatment: 1.an immature migratory (DCT+/PAX3+/c-KIT+) amelanotic (TYR-) 
population arising in the BG, maximally expressed in the INF and slightly diminishing in the IE; 2.a 
proliferative population (DCT+/PAX3+/c-KIT+/Ki67+), appearing in the upper INF and maximally 
expressed in the IE; 3.a differentiated non-proliferating population (DCT+/PAX3+/c-KIT+/TYR+) first 
seen in the INF and heavily expressed in the IE. Understanding the activation of these populations 
will facilitate the development of MC stem cell therapy as an approach for vitiligo repigmentation, 
now recognized as a classic example of regenerative medicine.    
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Animal-type melanoma: Two cases with aggressive behavior
R Vyas,1 K Honda,1,2 K Cooper1,2 and M Gerstenblith1,2 1 Department of Dermatology, 
University Hospitals Case Medical Center, Cleveland, OH and 2 Case Western Reserve 
University, Cleveland, OH
Animal-type melanoma (ATM) is a rare subtype of melanoma characterized by heavily pigmented 
spindled and epithelioid melanocytes and is reported to have a better prognosis than conventional 
melanoma. We performed a retrospective review of our pathology database and found two cases 
of ATM in the last 15 years. The first case is a 39-year-old African-American woman who presented 
with a rapidly growing scalp nodule found to be an ulcerated animal-type melanoma with Breslow’s 
depth 120mm, 5 dermal mitoses/mm2, vascular invasion, with local extension to periosteum. Five 
out of 65 lymph nodes contained metastases. Despite wide local excision and completion lymph 
node dissection, she rapidly developed recurrence locally as well as metastases to the cervical 
spine, lungs and meninges. BRAF V600E mutation testing was negative. She is currently undergoing 
palliative radiotherapy. The second case is a 90-year-old Caucasian man who presented with a 
right elbow nodule found to be an ulcerated animal-type melanoma with Breslow’s depth 6mm, 8 
dermal mitoses/mm2, and micro-satellitosis. He underwent wide local excision, though the deep 
margin was positive. Metastases to the brain and lungs were found, and he died four months after 
diagnosis. Although ATM is reported to have a good prognosis, our cases highlight that it can also 
display aggressive features with poor outcomes.    
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The metabolic state determines resistance to BRAF/MEK-inhibition
HR Widlund Dermatology, Brigham and Women’s Hospital, Boston, MA
To sustain continued proliferation, cells must adapt their metabolism to balance energy production 
with their augmented biosynthetic needs within the nutrient environment they reside. While most 
normal differentiated cells utilize oxidative phosphorylation for ATP generation through mitochon-
drial catabolism, cancer cells also rely on cytoplasmic anabolism to ensure adequate building block 
availability for their growth. This cancer-associated metabolic shift is termed the Warburg effect 
and is under intense scrutiny due to its promise for novel therapeutic strategies. The oncogene 
BRAF(V600*) has recently emerged as a major regulator of altered metabolic homeostasis. In order 
to bypass oncogene-induced senescence, oncogenic BRAF requires a metabolic shift from catabolic 
oxidative phosphorylation towards anabolic glycolysis during melanocyte-tumorigenesis. To this 
end, we have recently demonstrated a molecular rationale for this altered metabolism seen in a 
significant fraction of melanoma cells through a restricted melanocyte-lineage program involving 
the melanocyte-lineage factor MITF and the downstream mitochondrial biogenesis co-regulator - 
PGC1-alpha. Specifically, oncogenic BRAF-MEK signaling attenuates expression of MITF/PGC1-al-
pha, whereby targeted pharmacological inhibition of BRAF/MEK reverse this effect and increase ATP 
generation through oxidative phosphorylation. Our current work highlights that the effective cellular 
response to pharmacological BRAF/MEK-inhibition is determined by the inherent metabolic state, 
a premise guided by the paradoxical pre-existing clinical resistance to BRAF-targeted agents seen 
in a fraction of melanomas and other human tumors. In effect, cancer cells refractory to BRAF/MEK 
targeted therapeutics are less reliant on catabolic oxidative phosphorylation and exhibit hallmarks 
of a ground-state metabolism akin to stem cells. Our present work is an important extension and 
rational effort to uncover new opportunities to sensitize cancers by combinatorial strategies towards 
available therapeutic modalities that benefit patient survival.    
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Investigation on crosstalk between cAMP signaling and BRAF(V600E) in melanoma
CI Rodriguez,1,2 N Maddodi2 and V Setaluri2 1 Molecular and Environmental Toxicology 
Center (METC), University of Wisconsin - Madison, Madison, WI and 2 Dermatology, 
University of Wisconsin - Madison, Madison, WI
Cyclic AMP (cAMP) signaling, upon the activation of G-protein couple receptors (GPCR), is cru-
cial for melanocyte proliferation and differentiation. Although cAMP signaling has been shown to 
be downregulated in melanoma harboring a mutation in NRAS, relationship between GPCR and 
cAMP signaling and mutant BRAF is not understood. We studied the activity of four G-protein 
signaling pathways, Gαs, Gαq, Gα12, Gβγ, in melanoma, using luciferase reporters containing 
cAMP Response element (CRE), inositol triphosphate signaling response element (NFAT-RE), RhoA 
signaling response element (SRF-RE) and MAPK pathway response (SRE), respectively. Our data show 
cAMP signaling is highly and constitutively active in BRAF(V600E) mutant melanoma than in NRAS 
mutant melanoma cell lines. Increasing the intracellular cAMP concentration by activation of ade-
nylyl cyclase with forskolin decreased proliferation and migration of BRAF(V600E) melanoma cell 
lines. Intriguingly, in a melanoma cell line with neither BRAF nor NRAS mutation, hyperactivation 
of cAMP signaling increased its proliferation. Moreover, inhibition of BRAF(V600E) with PLX4320 
increased constitutive cAMP activity as measured by CRE-luciferase reporter assay. These results 
suggest a possible cross-talk between cAMP signaling and BRAF(V600E) sigaling in melanoma.   
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BRAF protein expression as a prognostic marker for thin melanomas
Y Cheng and Y Zhou Dermatology and Skin Science, University of British Columbia, 
Vancouver, BC, Canada
Predicting the chances of survival for melanoma patients has important implications in patient 
management. Numerous histological markers has been described in the literature. However, there 
has been a paucity of markers for thin melanomas which account for the majority of melanoma 
diagnosed at present. The objective for the current study is to search for molecular markers with 
potential for mortality prognostication of patients with thin melanomas. Clinically annotated mela-
noma biopsies from 788 patients of various stages of melanomas were analyzed in the format of high 
density tissue microarrays with immunohistochemistry staining for a serious markers. The intensity 
of each markers was analyzed in multivariate analysis for their independent prognostic significance. 
BRAF expression emerged as the only marker with prognostic potential for thin melanomas. This 
indicate that assessing expression levels of BRAF protein can help in the management decision 
making process for melanoma patients.    
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Melanoma patients’ communication preferences for biopsy result notification in an era of 
proliferating electronic messaging methods
A Choudhry,2 J Hong,2 K Chong,1 B Jiang,3 R Hartman,4 E Chu,4 K Nelson,3 ML Wei1,2 
and T Nguyen5 1 University of California, San Francisco, CA, 2 Veterans Affairs Medical 
Center, San Francisco, CA, 3 Duke University, Durham, NC, 4 University of Pennsylvania, 
Philadelphia, PA and 5 California Pacific Medical Center, San Francisco, CA
Rapid expansion in the number of electronic communication methods, e.g. online portals for 
patient access to electronic medical charts, raises the question of patient preferences for commu-
nicating biopsy results in the context of a possible malignancy diagnosis such as melanoma. This 
multi-center study surveyed the preferences of 298 patients seen in Pigmented Lesion Clinics at 3 
geographically disparate academic tertiary referral institutions over a 12-month period. Despite the 
availability of communication methods such as email, online portals (implemented as early as 5 
years ago at UPenn), texting and private tweets, overall patient preference was markedly (67%) in 
favor of receiving biopsy results via speaking with a healthcare provider by phone, followed by the 
distant second choice of being notified in person at a clinic visit (20%). At the institutions at which 
online portals have been implemented for over 2 years (UCSF, UPenn), this option was one of the 
least favored (2-3%), while at the institution (Duke) at which the online portal had not yet been 
implemented, but was anticipated, this option was chosen as the second choice (14%). Subgroup 
analysis showed that there was no significant gender difference in preferences and the youngest 
cohort (18-35 yo) and the college educated had the most favorable opinion of notification by online 
portal. Among patients who indicated a preference for a different mode of notification for benign 
vs. malignant results, voice mail was favored over all methods, including all electronic methods. 
Despite the rapid adoption of multiple electronic communication modalities by the general popu-
lace, patients currently prefer traditional methods of biopsy result notification. It will be interesting 
to track preferences as the youngest cohort ages and online portals become more established.   
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Selective inhibition of protein trafficking increases melanoma sensitivity to vemurafenib and 
blocks the development of resistance by down-regulating receptor tyrosine kinase signaling 
pathways
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We previously demonstrated that selectively targeting melanocyte-specific protein trafficking path-
ways in melanoma cells increases treatment sensitivity to multiple chemotherapeutic agents, includ-
ing cisplatin and carboplatin, by inhibiting the formation of melanosomes and the sequestration 
of chemotherapeutic agents into those organelles. Here we demonstrate that selectively inhibiting 
protein trafficking pathways in human melanoma cells by RNA silencing of the trafficking regulators 
VPS33A or cappuccino (CNO/BLOC1S4) also significantly increases sensitivity to vemurafenib, 
an FDA approved inhibitor of activated BRAF, and, significantly, also blocks the development of 
vemurafenib resistance in vitro. Susceptibility to vemurafenib correlates inversely with pigmenta-
tion in multiple cell types, and development of resistance correlates with increased pigmentation. 
Reported mechanisms of vemurafenib resistance include the up-regulation or activation of multiple 
receptor tyrosine kinases (RTKs) such as PDGFRβ, IGF-1R, KIT and MET as well as signaling mol-
ecules downstream of the RTKs. We find that inhibition of protein trafficking reduces total cellular 
levels of PDGFRβ, IGF-1R, MET and p-KIT as well as the downstream signaling molecules MEK, 
ERK1/2, AKT, mTOR, and p70-6SK. Furthermore, therapy combining protein trafficking inhibition 
and cisplatin or carboplatin with inhibition of either BRAF or phosphatidylinositol-3 kinase (PI3K)/
mTOR shows a markedly synergistic increase in treatment sensitivity compared with single or dual 
agent treatment by 30-200 fold. These data indicate that inhibition of protein trafficking offers a novel 
therapeutic approach that simultaneously increases the efficacy of multiple, mechanistically diverse 
therapeutic agents while preventing the in vitro development of acquired resistance to vemurafenib.   
   
      
